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ABSTRACT
Assessment of the Effects of Malaria and Anemia in Pregnant Malawian Women Before
and After Treatment of Moderate Malnutrition
William Shipley
Background: Moderate acute malnutrition (MAM) can lead to adverse maternal and
infant outcomes and possibly further complications. Supplementary foods or treatments
with high quality nutrients should be administered to those with MAM in hopes to
increase the chance of healthy maternal and infant outcomes. Sometimes supplementary
food is not enough to overcome MAM and disease may play a role, particularly in
pregnant malnourished women.
Objective: To determine if the effects of malaria and anemia moderated the effect of
nutritional treatments (one of the three given nutritional interventions) used to improve
malnutrition and achieve a MUAC ≥ 23 cm during study participation. Additionally, this
research serves to assess whether the relationship between malaria and anemia is
associated with malnutrition status.
Methods: Women were given a dose of IPTp at each antenatal visit between zero and
four total IPTp doses. Infant anthropometrics – length, weight, head circumference, and
MUAC were taken at birth, 6 weeks, and 3 months. Maternal hemoglobin levels were
assessed at enrollment and after 10 weeks of enrollment as well as infant hemoglobin at 3
months. Anemia was defined by a hemoglobin less than 11.0 g/dL. Mild anemia was
defined as hemoglobin greater than 7.0 but less than 9.9 g/dL and moderate anemia was
defined by hemoglobin values 9.9 or greater but less than 11.0 g/dL. Analysis was
completed using ANOVA, and if any significant differences were observed, they were
compared via Tukey HSD (continuous) or Chi-squared test (categorical).
Results: Total number of IPTp doses was found to be a more statistically significant
predictor of maternal weight gain during treatment than timing of the doses. It stands to
reason that women receiving three or more IPTp doses was the most beneficial for
women during treatment as it saw the highest increases in maternal weight gain. At
baseline, women that achieved a MUAC > 23 cm during the study was 32.0% (n = 1805).
The greatest proportion of women, after adjustment, that achieved a MUAC ≥ 23 cm was
seen in women receiving four (47.3 %) and three (37.8 %) total IPTp doses during
pregnancy. Maternal weight gain correlated closely with hemoglobin at enrollment (pvalue = 0.0111). Total number of IPTp doses received during pregnancy was not found to
have a statistical effect on infant hemoglobin or anemia at three months. Infant length at
six weeks was higher in infants from mothers that received two or three IPTp doses
compared to mothers that received one IPTp dose (p-value = 0.0218). A p-value below
0.05 by total number of IPTp doses was observed for infant weight, head circumference,
and MUAC at birth, six weeks, and three months.
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Conclusion: At least three IPTp was effective in improving maternal weight gain and
achievement of MUAC > 23 cm as well as improved many infant outcomes. Hemoglobin
at enrollment was a predictor of maternal weight gain during tx but was not associated
with any other outcomes.
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CHAPTER 1:
INTRODUCTION
Malnutrition is a serious global health issue, especially in developing countries.
Pregnant women with malnutrition are particularly susceptible to pregnancy related
complications due to the increased demand of many nutrients throughout the duration of
pregnancy, integral to fetal development (Darnton-Hill, 2015). Current research suggests
that maternal malnutrition may lead to poor fetal development resulting in low birth
weight, stillbirths, preterm birth, neonatal mortality, and halted linear growth (Papathakis
et al., 2016). There is a strong relationship between malnutrition and disease, particularly
in infants, because malnutrition leads to underweight and stunted children that are more
susceptible to disease. Illness only worsens a person’s nutritional status by ailments such
as diarrhea, malabsorption, and diversion of nutrients for an immune response. Energy
and micronutrient needs are increased with illness such as fever (Katona, 2008). In a
2005 study, the WHO estimated that more than half of all children deaths prior to 5 years
of age are due to five main diseases – pneumonia, diarrhea, malaria, measles, and AIDS.
94% of the global deaths for children under 5 are attributed to one of the main diseases
occur in the African region with undernutrition being a comorbidity in 53% of these
deaths (Bryce J, 2005).

Figure 1: The relationship between malnutrition and infection or disease (Katona, 2008).
Several factors contribute to and are responsible for malnutrition, such as,
personal health, socioeconomic status, and household food insecurity. Under nutrition
continues to be a significant problem in Sub-Saharan Africa. In 2005, the prevalence of
malnutrition was 24.3 % and continues to be a staggering 22.8 % as recent as 2018
(WFP, 2019). Malnutrition has been shown to increase the prevalence of comorbidities,
including, tuberculosis, diarrhea, malaria, and anemia (Bain, 2013). During pregnancy,
we see similar complications, such as anemia, increased risk of life-threatening
hemorrhages, and pre-eclampsia (Wu, 2012).
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CHAPTER 2:
LITERATURE REVIEW

2.1 Maternal Outcomes in Normal Pregnancy
2.1.1 Gestational Weight Gain
Pregnancy is a unique and complex biological condition, and central to that is
gestational weight gain, which supports growth and development of the fetus. Women
that are pregnant enter an anabolic state during which the body increases it’s overall
mass, fetal mass, blood volume, amniotic fluid, and placental growth (Rasmussen, 2009).
Recommended weight gain depends on women BMI, as shown in Figure 1, with higher
weight gain recommendations for women with lower BMI. The recommendations are
based on evidence that supports fetal growth and infant outcomes. (IOM, 2009).
Developed countries have seen increases in the prevalence of excessive
gestational weight gain (Kominiarek, 2017); however, in developing countries there is a
high prevalence of inadequate gestational weight gain to support optimal maternal and
fetal outcomes. This high prevalence of inadequate gestational weight gain has been
attributed to low food availability and nutrient intake. (Rasmussen, 2009). The IOM
recommends an average weekly weight gain during pregnancy in the 2nd and 3rd
trimesters of 0.434 kg (IOM, 2009). Weight gain and nutritional status during pregnancy
is positively related to fetal growth and infant outcomes, especially during the second and
third trimesters (Stein, 2004).
Many studies have shown a strong correlation between low gestational weight
gain and low birthweight. A study done by Frederick et al. showed that women gaining
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less than the median gestational weight gain, or 15.9 kg during pregnancy, was associated
with twice the risk of low birthweight after adjusting for covariates (Frederick, 2008). A
large meta-analysis done by Han et al showed that low total gestational weight gain,
between 11.5 and 12.5 kg, was associated with increased risk of low birthweight in
developing countries, which suggests that a weekly gain of 0.3 kg is indicative of
increased risk for low birthweight; however, the meta-analysis also only showed a
statistical correlation between weekly gestational weight and preterm birth, but not low
birthweight (Han, 2011).

Table 1: Institute of Medicine Weight Gain Recommendations for Pregnancy
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Adapted from Institute of Medicine (IOM), 2016.

2.1.2 Maternal MUAC
Mid-upper arm circumference (MUAC) can be a useful indicator for maternal
malnutrition as well as predict low birthweight. The arm has both subcutaneous fat and
muscle, so changes in MUAC may indicate a change in sub-cutaneous fat as well as
muscle (Kumar, 2018). In low socioeconomic areas and regions with limited resources
available, individuals tend to have smaller amounts of subcutaneous fat, changes in
MUAC are closely associated with changes in muscle mass (Tang, 2016). MUAC > 21
4

cm is commonly used a cut-off for severe malnutrition and MUAC > 23 cm for moderate
malnutrition. An observational study done in India showed a MUAC > 23 cm to be a
good predictor of low birthweight as seen in Figure 2.

Figure 2: Linear Correlation of Birthweight and Maternal MUAC. (Adapated from
Vasundhara, 2019).
2.2 Malaria and Preventative Treatments
2.2.1 Malaria
Malaria, according to the WHO, is a life-threatening disease caused by parasites
that are transmitted to people through bites from carrier female Anopheles mosquitos.
The disease is a preventable and curable one. Malaria is caused from a Plasmodium
parasite, of which there are five different species of these parasites that may cause a
malarial infection. The two most common species are P. falciparum and P. vivax. P.
falciparum is the most common malarial parasite on the African continent and is
5

responsible for most of malarial-related deaths worldwide, while P. vivax thrives in most
countries outside of Africa (WHO, 2020).
Symptoms of malaria begin as fevers and headaches; and may be difficult to
diagnose as malaria. It is crucial that symptoms be treated as soon as possible,
preferentially within the first 24 hours of infection because it may progress to a severe
illness and can result in death. It is common for infants with malaria to develop anemia,
metabolic acidosis, or respiratory stress. Anemia and malaria are prevalent comorbidities
throughout most of the African continent, which increases the importance of early
diagnosis and treatment. Another reason for the importance of early diagnosis of malaria
is to prevent spreading infection throughout local communities; malaria should be treated
as a medical emergency. The Centers for Disease Control and Prevention (CDC) identify
late diagnoses of malaria as being the leading cause of death in malaria patients
throughout the United States (CDC. 2019).
According to the WHO, World Health Organization, there are approximately 3.4
billion people worldwide throughout 91 different countries that are at risk for developing
malarial disease, and of those 3.4 billion, 1.1 billion are considered at high risk, or more
than one person out of every thousand people will develop malaria in a calendar year.
The World Malaria Report reported 228 million cases of malaria throughout the globe in
2018, which led to 405,000 deaths. The WHO reported that roughly 94% of all malarial
deaths occurred within the African Region (WHO, 2019). Even though malarial is a
worldwide disease, over 90% of cases are from African populations where the malarial
parasite affects mainly young infant and pregnant women (Snow, 2005).

6

2.2.2 Consequences of Malaria
Malaria has severe implications on nutritional status, especially if the person is
already malnourished. Pregnant women have a higher risk than non-pregnant women of
being malnourished due to the increased nutrient needs (Unger, 2016). This can be
especially dangerous in high-risk countries susceptible to malaria such as Sub-Saharan
African populations (Rogerson, 2017). Macronutrient deficiency has been associated with
increased morbidity and mortality related to malaria in infant, non-pregnant adults, and
pregnant adults. These findings suggest malaria is instrumental in interactions with the
immune system (Shankar, 2000). Malaria has been shown to cause nutritional depletion
and worsen nutrient status in already undernourished populations, especially infants
(Rogerson, 2017). Malnourished women with malarial infections have a significantly
more profound effect on fetal growth as well as birth weight than in well-nourished
women with malaria (Nyakeriga, 2004). In a study conducted in the Democratic Republic
of Congo, they found that undernourished women with early pregnancy malaria, with low
MUAC and BMI, had a 3.6 times increased risk of having infants with stunted growth
(Griffin, 2012).
2.2.3 Malaria Prevention During Pregnancy
According to a study by Feng et al, between 1999 and 2006, the use of bed nets in
Malawi went from 14.4 % during pregnancy to 60.5% and showed a significant
association with decreased malarial contraction, an odds ratio of 0.47 [CI 95%: 0.37,
0.60], and infant low birthweight, but was unable to show a decrease in anemia. In the
study, infant birth weight was 47 g higher on average in women using bed nets compared
to non-users (Feng, 2010). The use of bed nets in conjunction with at least two doses of
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SP IPTp during pregnancy also showed a significant decrease in rates of infection with
malaria and low birth-weight compared to no bed net use with zero or one doses of SP,
odds ratio 0.38, [CI 95%: 0.27, 0.53]. Women with at least two doses of SP IPTp and
without the use of bed nets did not show a significant decrease in malaria infection, odds
ratio 0.87 [CI 95%: 0.67, 1.13] (Feng, 2010). Another study showed that three or more
doses of IPTp decreased the incidence of low birthweight from 9.9 % to 6.9 % (Cates,
2018).
SP is a common low-cost treatment for pregnant women in Sub-Saharan regions
at Antenatal Clinics for the prevention of contracting malaria. In 2020, the WHO recently
issued new guidelines outlining the use of SP from two or more doses to one dose at
every scheduled antenatal clinic (ANC) visit beginning in the second trimester (WHO,
2020). This new guideline stems from a meta-analysis of seven trials that showed three or
more doses of SP were much more effective at overall malarial prevention, reducing risk
of infection by as much as half, than the previous two-dose recommendation. Also, there
is evidence that three of more doses of SP as IPTp has a greater chance to reduce the risk
of severe maternal anemia and adverse birth outcomes, such as low-birth weight than the
former two-dose recommendation (Kayentao, 2013). It is important that each facility
using SP as IPTp continue to monitor SP efficacy and molecular resistance markers
because almost 70% of malarial cases are resistant to both cholorquine and SP
antimalarials.
SP is a combination drug composed of sulfadoxine and pyrimethamine.
Sulfadoxine works mechanistically is by targeting Plasmodium dihydropteroate synthase,
which converts dihydropteroate diphosphate and p-aminobenzoic acid (PABA) to
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dihydropteroic acid. Specifically, SP acts competitive inhibitor of the enzyme, competing
with PABA for incorporation into folic acid. As Figure 3 indicates, this inhibited step is
crucial for the synthesis of folic acid, which is vital in the synthesis, methylation, and
repair of DNA. Without folic acid, the Plasmodium falciparum bacterium have difficulty
in reproduction since they are unable to get folic acid from host cells because folic acid
does not diffuse through bacterial cell walls (Shultz, 1994).

Figure 3: Folate Metabolism. (adapted, Crider, 2012).
Pyrimethamine is similar to sulfadoxine but inhibits dihydrofolate reductase (DHFR)
instead of DHPS. Inhibition of dihydrofolate reductase is associated with blocking the
biosynthesis of purine and pyrimidine nitrogenous bases. This leads to failure to replicate
DNA and the bacterial cell is unable to reproduce (Shultz, 2013).
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Figure 4: Chemical Structure of Sulfadoxine and Pyrimethamine. (PubChem, Accessed
June 16th, 2020).

2.2.4 Malarial Treatment During Pregnancy
Lariam, mefloquine, is generally the drug of choice when treating malaria in
endemic areas of the world such as Sub-Saharan Africa. In 2013, Lariam was reclassified
as a pregnancy category B drug, though initially was a category C drug (FDA, 2013).
Category B drugs are classified as drugs that have failed to demonstrate a risk to the fetus
in animal reproduction but haven’t been in many well-controlled studies with pregnant
women. Category C drugs are classified as having shown an adverse effect on the fetus
in animal reproduction and should be used cautiously when treating pregnant women.
(Federal Register, 2017). Lariam has at least five major characteristics that make it a
desirable choice for malarial treatment: a long half-life of between 14 to 28 days, a single
dose administration, a well-researched pharmacokinetic profile in pregnant women,
infrequent MQ resistance in Sub-Saharan Africa, and an acceptable level of toxic side
effects during reproduction in animal studies (Briand, 2009; Bangchang, 1994; Nosten,
1990; Ward, 2007). Mefloquine has been found to be effective against malaria parasites
that are resistant to chloroquine or sulfadoxine-pyrimethamine. It’s mechanism of action
involves erythrocytes within the Plasmodium species. It is known as a blood
schizonticide, which destroys shizonts in the blood stream. Shizonts are mature malaria
parasites that infect the red blood cells of the human host (Schlagenhauf, 1999).
10

2.2.5 Malarial Resistance
With a continued expansion of Plasmodium falciparum resistance to antimalarial
therapies, malarial control and antimalarial strategies are important in high at-risk
populations such as sub-Saharan African populations. In 1993, chloroquine was
discontinued as the predominant chemotherapy drug and replaced by sulfadoxinepyrimethamine (SP) in Malawi, and used to prevent and treat uncomplicated malaria due
to a high resistance response; however, within the next decade, chloroquine-susceptible
parasites reemerged in Malawi (Artimovich, 2015). Within the decade following 1993,
parasite resistance to sulfadoxine-pyrimethamine (SP) was seen (Kublin, 2002).
Plasmodium falciparum develop or adapt sulfadoxine-pyrimethamine resistance
polymorphisms within the dihydrofolate reductase-thymidylate synthase (encoded by
pfdhfr-ts) and dropteroate synthase genes (encoded by pfdhps) (Kublin, 2002). More
specifically, mutations occur at three different codons of the Pfdhfr gene: N51I, C59R,
and S108N. Mutations at these codons is commonly referred to as the triple mutation;
whereas, mutations at the A437G and G540E codons within the Pfdhps gene are referred
to as the double mutation (McCollum, 2010). Studies in Eastern Africa have shown the
emergence of a third mutation within the Pfdhps at codon 581G, which in conjunction
with the other five mutations makes a sextuple mutation (Spalding, 2010). This is
especially important when considering the use of IPTp and SP treatment for prevention of
malaria because there is evidence that sextuple mutations are associated with reduced
birth weight and increased risk of parasitemia and placental infection by Plasmodium
falciparum, which suggests that SP contributes to malaria in women with sextuple mutant
strains (Harrington, 2013; Minja, 2013). Table 1 shows the prevalence of each of the six
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mutations observed in P. falciparum-positive women during pregnancy in a recent study.
Overall, the proportion of P. falciparum-positive was 128/998 or 12.8%. 8/101 or 8% of
women were observed carrying the sextuple mutant, which indicates that SP-IPTp
treatment is losing efficacy and may become ineffective overtime (Anthony, 2015). There
has been no evidence of parasite-susceptibility to SP after discontinued use for several
years, unlike that seen with chloroquine (Artimovich, 2015). These findings show a
difficulty factor associated with anti-malarial and first-line treatments when dealing with
high-risk populations.
Table 2: Prevalence of Pfdhfr and Pfdhps Single and Haplotype Mutations Among
Febrile Pregnant Women Presenting at Outpatient Clinicsa (Mbonye, 2015).
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2.3 Hemoglobin and Anemia
2.3.1 Types of Anemia
Anemia is defined by the World Health Organization (WHO) as a hemoglobin
concentration below 11.0 g/dL and as of 2016, has high prevalence in both developed and
developing countries, being the highest in South-East Asian at 48.1 % followed by Africa
with a prevalence rate of 46.2 % (WHO, 2017). The most common types of anemia are
iron-deficiency anemia, pernicious anemia, aplastic anemia, and hemolytic anemia. Irondeficiency anemia is the most common type of anemia, and iron is essential in human
energy production, oxygen transport, oxygen utilization, cell proliferation, and pathogen
destruction. Iron-deficiency primarily occurs in persons with increased iron requirements,
such as children, adolescents, women during childbearing years, and pregnancy. With
diminished oxygen carrying capacity due to iron-deficiency, symptoms of weakness,
fatigue, shortness of breath, and decreased physical capacity are common (Lynch, 2018).
Pernicious anemia is a direct result of vitamin B-12 deficiency and results in
megaloblastic, or larger than normal, red blood cells. Vitamin B-12 deficiency is not
always a from lack of dietary intake, but is a consequence of intrinsic factor deficiency
due to the parietal cells in the corpus of the stomach not producing enough intrinsic factor
to assist in Vitamin B-12 absorption in the small intestine (Toh, 2004).
2.3.2 Anemia in Pregnancy
Iron is needed in the greatest quantities during the third trimester, where the most
iron is transferred to the fetus (WHO, 2015). The most iron transferred to the fetus occurs
after 30 weeks of gestation (Allen, 2000). Iron absorption is increased during iron
transfer from the mother to fetus and is regulated by the placenta. Typically, serum
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ferritin significantly decreases between weeks 12 to 25 of gestation to increase iron
utilization as red blood cells are synthesized (Harris, 1992). Figure 1 depicts serum
transferrin transporting iron from maternal blood to transferrin receptors on the epithelial
surface of embryonic placental villi, then holotransferrin is endocytosed, iron is released
in the fetal blood, and apotransferrin returns to the maternal blood. Then, a similar
cascade occurs where iron binds to ferritin in placental cells, which is then transferred to
apotransferrin, enters the fetal side of the placenta, and enters the fetal blood stream as
holotransferrin (Starreveld, 1995). With low maternal iron status, there is an increased
number of placental transferrin receptors to promote iron uptake by the placenta, thus
leaving the mother at greater risk for iron-deficiency anemia (Allen, 2000).
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Figure 5: Transfer of iron from mother to fetus (Mcardle, 2011).
2.3.3 Anemia Risk Factors
There are several risk factors for anemia in general, such as: malaria,
schistosomiasis, tuberculosis, HIV/AIDS, geophagia, parasites, and socioeconomic status
(WHO, 2015). Parasites, such as Plasmodium falciparum, significantly increase the risk
of iron deficiency anemia during pregnancy. Malaria prevention is a key focus to
lowering the risk of iron deficiency anemia in malaria endemic areas such as Africa and
South America (Anlaakuu, 2017). Low socioeconomic status shows the highest risk for
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iron deficiency anemia in infant and pregnant women – there is the least access to
interventions, treatments, and services (Mawani, 2016).
Nutritional considerations with iron-deficiency anemia are based on the two main
forms of dietary iron: heme and nonheme. Generally, heme iron is found in meats and
nonheme iron is found in meats, as well as plant-based foods. Some dietary
considerations with iron to consider are absorption enhancers and inhibitors. Inhibitors of
iron absorption include dairy products, eggs, polyphenols such as in coffee, phytates,
divalent cations, and oxalates. Enhancers of iron absorption include fruits and vegetables.
Some challenges specific to Sub-Saharan African regions include limitations to
availability of iron rich foods as well as high costs (Mwangi, 2017). From a
bioavailability standpoint, there is evidence that African diets are low in ascorbic acid, or
Vitamin C, which enhances the absorption of iron, as well as low bioavailability of iron
due to diets high in legume and cereals, containing inhibitors of iron absorption
(Zimmerman, 2005).
The WHO has developed guidelines specifically for the prevention, control, and
treatment of anemia in reproductive age women. Daily iron and folic acid
supplementation is recommended as part of antenatal care (ANC), especially in areas
where the prevalence of anemia is above 20% (WHO, 2017). Iron recommendations for
pregnant women is 27 mg per day, but for iron-deficient anemia, 60-180 mg per day
should be consumed (Woteki, 1993). The management of malaria control, such as IPTp
or use of bed nets is important in prevention and control of anemia. The WHO also
promotes education on anemia and basic hygiene as preventative measures (WHO, 2017).
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2.3.4 Consequences of Anemia During Pregnancy
Common iron-deficient anemia complications are an increased maternal cardiac
output, which leads to fatigue; and for infants, risk is increased for low-birth weight, premature delivery, abortion or still birth, and low iron stores at birth (Jung, 2019). If irondeficient anemia occurs during early pregnancy, risk for preterm and low-birth weight
increased by two-to-three times normal risk. Iron-deficient anemia during late pregnancy
has shown a risk for lower scores on intelligence, language, gross motor, and attention
tests in infant. Infants are at high risk for impaired physical and cognitive development
and increased mortality (Rahman, 2016). Anemia is a major factor in maternal deaths,
and women with severe anemia are as high as 2.36 times more likely to die than women
without severe anemia (Daru, 2018).
Anemia during pregnancy has been associated with increased risk of still birth,
neonatal deaths, and low birthweight babies (Patel, 2018). Another study conducted in
China showed similar results, with anemia in pregnant women leading to an increase in
the prevalence of preterm birth, low birthweight, and neonatal complications. They also
found increased prevalence of anemia in lower socioeconomic areas (Lin, 2018) which is
consistent with another study in Pakistan (Ayub, 2009).
2.4 Malawi
2.4.1 Maternal and Infant Statistics in Malawi
Malawi is a small country in the southeast region of Sub-Saharan Africa and has
a reported population near 18,098,000 as of 2016 (WHO, 2018). The maternal mortality
rate was 634 deaths per 100,000 live births in 2015 and has been decreasing by an annual
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rate of 2 % since 1990 (UNICEF, 2020). As of 2018, the maternal mortality rate
decreased to 439 deaths per 100,000 women but remains one of the worst in the world
with the 13th highest rate. The infant mortality rate has steadily decreased from 76 deaths
per 1,000 births in 2004 to 35 deaths per 1,000 births in 2018 (UNICEF, 2018).
Within Malawi, there were 5,830,741 reported confirmed cases of Malaria in
2018, with as many as 11,513,684 suspected cases, which is over half of the entire
population of 18,600,000 – Roughly one in every four persons in Malawi have a
confirmed case of Malaria – of those reported cases, all are due to the Plasmodium
species. Of all the confirmed cases of malaria, approximately 4,000 people died. (WHO,
2018).
Malnutrition remains a problem in Malawi for women and children. In addition to
high stunting levels, ranging from 30 to 43 percent, 63 percent of children under five are
anemia and 33 percent of women are anemic (USAID, 2018). In 2000, UNICEF reported
15.9% of all infants had low birth-weight (LBW), which by definition is weighing less
than 2.5 kg. By 2006, 12.5 % of infants were born with LBW, which by comparison is a
significant decrease from the year 2000; however, the trend did not stick, in 2010, the rate
of LBW was 13.5 % (UNICEF, 2018).
Micronutrient deficiencies are common in Malawi; and in 2001, the Ministry of
Health’s Micronutrient Survey showed that 60 % of infant under 5 had low vitamin A
status. Vitamin A is a vital component of proper immune function and healthy growth and
development of infant, and low Vitamin A status lowers the chance of infant surviving
serious illnesses. Low vitamin A status is a result of diets low in caloric and nutrient
intakes, disease, and chronically malnourished pregnant and breastfeeding women
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(UNICEF, 2010). Vitamin A status has improved significantly since 2001; as recently as
2016, vitamin A deficiency prevalence was very low with 4% of infant under 5 and less
than 1% of the remaining population. This positive result with vitamin A deficiency is
thought to be attributed to vitamin A supplementation in infant. Zinc deficiency was a
major micronutrient that had a range between 60 and 66 % of the total population being
zinc deficient. Zinc is an important micronutrient for normal infant growth, proper immune
function, and healthy pregnancies. Zinc deficiency may be caused by excess losses,
inadequate dietary intake, and malabsorption. Iron deficiency was reported to be 22 % in
infant under 5, 18.2 % in pregnant women, and 15 % in reproductive age women (UNICEF,
2018). A major challenge for Malawians to receive proper nutrition is household food
security status, or the ability of the household to obtain adequate food for the entire family
(UNICEF, 2018).

Figure 6: Reported data on Malawi micronutrient status from 2015-2016 (UNICEF,
2018).
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2.5 Conclusion
Overall, maternal and infant outcomes continue to be a public health issue in
Malawi. Rates of maternal weight gain, on average, are below recommended weekly
weight gain during pregnancy and prevalence of anemia is high. Infant outcomes remain
low on growth charts and while improving, maternal and infant mortality rates continue
to be some of the highest in the world. Increasing energy and micronutrient intakes,
through supplementation, relative to increased needs during pregnancy is an ideal
approach to improving maternal and infant outcomes; however, more research is
necessary to further understand and develop a successful treatment plan for malnourished
pregnancies (Papathakis, 2016).
Disease has been shown to play a role in maternal and infant outcomes,
particularly malaria in high-transmission risk regions, such as Sub-Saharan Africa. The
WHO released guidelines for intermittent preventative treatment in these high-risk areas,
recommending women receive a minimum of three IPTp doses for improved infant
outcomes (WHO 2020). To our knowledge, there aren’t studies that examine the
relationship between IPTp dosing and maternal weight gain or MUAC (cm). The current
study seeks to find results consistent with the WHO recommendations for improved
infant outcomes as well providing additional information on the effects of IPTp dosing on
maternal outcomes not previously studied. Anemia and hemoglobin levels are also
examined in this study to assess if a relationship exists between IPTp dosing and anemia
status and the effects on maternal and infant outcomes.
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CHAPTER 3:
METHODS AND MATERIALS
3.1 Methods and Objective
The objective of this research was to determine if the effects of intermittent
preventative treatment in pregnancy specific to malaria as well as anemia influenced
maternal weight gain and achievement a MUAC ≥ 23 cm during study participation.
Additionally, this research serves to assess whether the relationship between IPTp and
anemia influences infant health outcomes.
•

Research questions to answer through data analysis:
o Does hx of malaria, malaria during study, anemia and hemoglobin level at
enrollment and measured after 10 weeks of enrollment the participants
ability to achieve MUAC ≥ 23.0 cm through nutritional intervention?
o Does anemia severity, mild and moderate, predict weight gain during
treatment and achievement of MUAC ≥ 23 cm?
o The objective of this research was to determine the effects of maternal
hemoglobin, anemia, total maternal IPTp doses, maternal IPTp doses in
the second and third trimesters, and bed net use on maternal weight gain,
recovery from moderate malnutrition (MUAC ≥ 23 cm), and infant
outcomes – weight, length, head circumference, and MUAC at birth, six
weeks and/or 3 months as well as infant hemoglobin (measured at 3
months), length-for-age (LFA or stunting), and weight-for-age (WFA or
underweight)?

•

Hypothesis for each research question:
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o Women with malaria or anemia are less likely to achieve a MUAC ≥ 23.0
cm during study.
o Maternal hemoglobin, anemia, number of IPTp dose therapy by trimester
as well as total number of IPTp doses, illness, and bed net use predict
infant outcomes at birth, six weeks, and three months. I expect women that
report hx of malaria, malaria during study, lack of bed net use, and have
low hemoglobin status to have infants with z-scores at least 1 standard
deviation below average for length and weight; as well as head
circumference, MUAC at birth, six weeks, and three months and
hemoglobin at 3 months.
o IPTp dose therapy in pregnant women is for the prevention of malaria and
is common in high-risk regions such as Malawi. Women receiving three or
more IPTp doses will have a significantly higher mean MUAC at delivery,
and give birth to infants with significantly higher z-scores, head
circumference, MUAC, and hemoglobin levels than the results of women
receiving less than three IPTp treatment doses, which is consistent with
WHO recommendations.
3.2 Study Participants
This research was a secondary analysis of a large assessor-blinded randomized
controlled clinical trial. which assessed providing the Malawian standard of care when
treating moderate malnutrition in pregnancy against two other nutrition interventions –
between March 2014 and December 2015, 15 antenatal clinics in southern Malawi
recruiting pregnant women with moderate malnutrition into the Mamachiponde study.
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The 15 antenatal clinics were within the Blantyre, Chikhwawa, Mulanje, and Zomba
health districts.
Between March 2014 and December 2015, 15 antenatal clinics in southern
Malawi recruited pregnant women with moderate malnutrition into the Mamachiponde
study. The 15 antenatal clinics were within the Blantyre, Chikhwawa, Mulanje, and
Zomba health districts.
Inclusion criteria for the Mamachiponde study:
o ≥ 16 years old
o Hemoglobin ≥ 7.0 g/L
o Moderate malnutrition as defined by a MUAC ≥ 20.6 cm to ≤ 23.0 cm
o Willing to attend antenatal clinical visits every two weeks throughout
pregnancy and remain in the area for delivery and until 3 months
postpartum
o Consented to participate in the study via written and verbal consent
o Consent to HIV testing if not done previously
Exclusion criteria for the Mamachiponde study:
o Severe malnutrition as defined by a MUAC < 20.6 cm
o Pregnancy complications, such as preeclampsion, hypertension, and
gestational diabetes
o

< 16 years old

o Severe anemia as defined by a hemoglobin level < 7.0 g/L
o Participation in another nutrition study or nutritional intervention program
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In this sub-study, women receiving more 5 doses of IPTp were excluded due to
the limited sample size. After the exclusion criteria were taken into account, the total
sample size used was 1805.
3.3 Randomization and Blinding
Study participants were randomized into blocks of 60 and received one of the
three nutritional intervention treatments (RUSF, CSB-UNIMMAP, or CSB-IFA) via a
random number generator, which assigned each subject to a lettered group A, B, or C.
Each participant received a pregnancy ID number by picking an envelope with the
enclosed ID number contained inside. The research team was also blinded to treatment
groups for each study participant. Each participant was given a large opaque bucket, so
the researchers were unable to differentiate between different nutritional intervention
foods. Nurses involved in the study were aware of which treatment group each participant
was in, and this was necessary to provide proper preparation or consumption instructions
of intervention foods to each study participant. Upon completion of enrollment
measurements and information at the clinics, the study subject would collect her food and
be transported by a study driver, who was responsible for matching pregnancy ID number
to corresponding treatment group and confirm appropriate intervention food was
received. Study participants were unable to be blinded to which treatment group they
were a part of because the RUSF, CSB-UNIMMAP, and CSB-IFA are visually different
from each other. All data entry and analysis members were blinded to group assignments.
3.4 Study Design
Mamachiponde is a researcher-blinded, randomized controlled trial designed to
determine whether a micronutrient-fortified ready-to-use supplementary food (RUSF) or
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a fortified corn-soy blended flour (CSB+) plus a multiple micronutrient supplement
provided to pregnant women in Malawi, Africa with moderate malnutrition (defined as a
MUAC ≥ 20.6 cm to ≥ 23.0 cm) improved recovery from malnutrition and improved both
maternal and infant birth outcomes, compared to women receiving the standard of care
supplements. Standard of care supplemental food is a fortified CSB flour plus both daily
iron and folic acid supplements (CSB-IFA). CSB-IFA is the control intervention. Each
treatment food was given to participants in a 14-day supply.
The three intervention groups are described in detail below:
1) RUSF: This treatment provided 900 kcal/day, 38 g protein/day, and 200% of
the Recommended Dietary Allowance (RDA) for most micronutrients during pregnancy
(except for vitamin A, vitamin B3, folic acid, iodine, magnesium, and calcium, which
will remain near 100%). The energy content of RUSF was designed to provide 360-450
calories required during the second and third trimesters of pregnancy, and an additional
450-550 calories to support recovery from moderate malnutrition. Women randomized to
this treatment arm did not receive any additional supplements since micronutrients were
already in the formulated food.
2) CSB + UNIMMAP: This treatment included 5 kg every two weeks of a cornsoy
blended (CSB+) flour plus a standard antenatal micronutrient tablet (UNIMMAP) that
contains 15 micronutrients, which together provided a similar amount of energy, protein,
and micronutrients as the RUSF treatment.
3) CSB-IFA: This is the control group, which is the Malawian standard of care
treatment for moderate and severe malnutrition during pregnancy. This treatment
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included 5 kg CSB every two weeks plus daily iron (60 mg) and folic acid (400 mcg)
supplements. Enrolled women visited the clinic every 2 weeks for measurements, health
checks and received their two-week supply of treatment food. Women who achieved a
MUAC > 23.1 cm were considered ‘graduated’. Women whose MUAC remained > 23.1
cm for two consecutive visits no longer received food treatment, however, she still
received iron and folic acid supplements. After graduation, women came to clinic every
month to ensure no relapse into malnutrition had occurred. If relapse (MUAC <23.1)
occurred, mothers went back onto their assigned treatment food/supplements. Women
who graduated and/or relapsed were still included in the analysis.
All participants visited the clinic every two weeks for anthropometric
measurements, check-up on health status, and receive the next 14-day supply of their
nutritional intervention food. Women measured with a MUAC > 23.1 cm at any point
during their interventional time were considered as graduated or no longer moderately
malnourished. If these women maintained graduated status for two or more consecutive
visits, then they no longer received the food supplement, but only received an iron and
folic acid supplement. After graduating, women were required to visit the clinic monthly
to check for relapse back to malnourished status. If women relapsed, they were given
their previously assigned nutritional intervention food again.
3.5 Data Collection
Eligible women that were willing to consent to the study requirements had
anthropometric measurements recorded by a study team member at each antenatal clinic
visit every two weeks following enrollment. The measurements recorded at each visit
included weight, height, MUAC, tricep skinfold (TSF), and blood pressure. Weight was
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measured in kilograms with a Detecto Slimpro scale and height was recorded in
centimeters with a Seca Stadiometer. MUAC was measured twice using TALC
measuring tape - an additional third measurement was taken if the first two measures
differed by more than 1 mm and the closest two measurements were used.
3.6 Statistical Analysis
Statistical analysis was done using JMP Pro 13.1 software. Analyses included
ANOVA, logistic regression, two sample t-test, Chi-square analysis, and Tukey HSD test.
Continuous variables were analyzed by univariately by ANOVA and logistic regression.
Chi-square analysis was used to analyze categorical data univariately. For multivariate
analyses, continuous variables were looked at using Tukey HSD to determine the effect
of an individual variable after taking all the other model variables into account.
Categorical multivariate analysis was done by using odds ratios.
Variables created included number of IPTp doses (count), which was created by
adding total number of IPTp dose dates for each study participant. IPTp doses up to 10
weeks of enrollment was created to assess whether IPTp dosing during the first 10 weeks
of study enrollment had an effect on hemoglobin. IPTp doses by trimester was a variable
created by using the estimated age of gestation at enrollment and date of IPTp dose. Mild
and moderate hemoglobin (anemia) was created by using a data filter to only include data
within the ranges defined – mild defined greater than 7.0 g/dL and less than 9.9 g/dL and
moderate greater than or equal to 9.9 g/dL and less than 11.0 g/dL.
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CHAPTER 4:
RESULTS
4.1 Baseline: Maternal Characteristics
The age range for the 1805 study participants was 16 to 45 years old. BMI at
enrollment ranged from 15.3 kg/m² to 24.1 kg/m². On average, women enrolled in the
study at 24.5 weeks gestation. Over 20 % of women reported illness within 2 months of
enrollment into the study, of which, 13.5 % are attributed to malaria. Weight gain during
treatment in this context refers to weight gain from enrollment to delivery, which on
average was low, 0.269 kg, compared to the recommended or expected weight gain
during pregnancy of 0.454 kg per week (Rasmussen, 2009). The group enrollment was as
followed: 604 (33.5%) were in the RUSF group, 599 (33.2%) in the CSB-UNIMMAP
group, and 602 (33.4%) in the CSB-IFA group, p. Additional baseline maternal
characteristics are listed in Table 3.
Table 3: Baseline and Follow-up Maternal Characteristics
N = 18052

Characteristic
Age, years
BMI at Enroll (kg/m²)
Weeks Gestation at Enroll
MUAC at Enroll (cm)
MUAC at Delivery (cm)
Weeks on Treatment
Weight gain during tx (kg)
Characteristic
Clinic Region
Blantyre
Chikhwawa
Mulange
Zomba
Season

1760
1505
1799

314
739
87
665
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Mean1
21.6±5.3
19.7±1.4
24.5±6.4
22.3±0.6
22.2±0.9
9.08±5.7
2.69±2.6
%
17.4
41
4.8
36.8

Rainy
Dry
Achieve MUAC ≥ 23 cm
Hx of Illness
Hx of Malaria
Hx of Iron supplement
Hx of Folate supplement
Malaria during tx
Bed Net Use during tx

568
1237
578
363
243
996
50
111
1410

31.5
68.5
32.7
20.1
13.5
55.2
2.8
6.5
78.1

1

Values expressed as Means and Standard Deviation (SD) or Percentages (%)
Sample size N is 1805 unless otherwise specified in column.

2

4.2 Unadjusted Maternal Health Outcomes by IPTp Dosing
Women received between zero and four IPTp doses during pregnancy with most
receiving two total IPTp doses. Not all doses were received during the study; maternal
records were reviewed and, prior IPTp dosing was recorded. Most women received no
IPTp (95.6 %) doses during the 1st trimester, consistent with WHO guidelines on IPTp
dosing during the 1st trimester (WHO, 2020). IPTp dosing during the 2nd trimester ranged
between zero and four doses; however, four doses during the 2nd trimester was only
recorded for one woman, with the majority of women receiving 1 dose in the 2nd
trimester. The 3rd trimester had a range of zero to three IPTp doses with the majority of
women receiving one IPTp dose.
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Table 4: Distribution of IPTp Doses Among Women Enrolled
Characteristic
Total Number IPTp Doses during pregnancy
0
1
2
3
4
IPTp Doses in 1st Trimester
0
1
2
IPTp Doses in 2nd Trimester
0
1
2
3
4
IPTp Doses in 3rd Trimester
0
1
2
3
1

Values expressed as n and percenaget (%).
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N = 1648

%

43
363
745
442
55

2.6
22
45.2
26.8
3.3

1576
65
7

95.6
3.9
0.4

292
955
383
17
1

17.7
58
23.2
1
0.1

541
717
343
47

32.8
43.5
20.8
2.9

Table 5: Maternal Characteristics Compared Across Number of IPTp Doses Reported
During Pregnancy

Characteristics

0
n = 43
22.6±0.8ab

Total Number of IPTp Doses (n = 1648)
1
2
3
4
n = 363
n = 745
n = 442
n = 55
a
b
ab
21.7±0.3
20.7±0.2
21.1±0.2
20.7±0.6ab

Subject Age
MUAC at
Delivery
22.3±0.2
22.1±0.1
4
(cm)
Wt. Gain
during
2.42±0.4abc 1.97±0.1b
treatment (kg)
Δ in
Hemoglobin
1.30±0.3
1.40±0.1
5
(g/dL)
Hemoglobin
10 weeks after 11.43±0.3 11.38±0.1
Enroll (g/dL)5

Malaria
during Tx
Achieve
MUAC ≥ 23
cm

Overall

P-value

21.1±0.1

0.0036

22.2±0.03

22.2±0.05

22.3±0.1

22.2±0.02

0.2274

2.61±0.1a

3.34±0.1c

3.8±0.3c

2.70±0.1

<0.0001

1.20±0.1

1.13±0.1

0.73±0.2

1.20±0.1

0.0907

11.47±0.1

11.32±0.1

10.94±0.2 11.39±0.04

0.1693

% (n)

% (n)

% (n)

% (n)

% (n)

Overall
% (n)

P-value

4.7 (2)

7.4 (27)

7.5 (56)

5.2 (23)

5.5 (3)

6.5 (111)

0.5418

32.7 (539)

0.0020

27.9 (12)a

26.7 (97)a 31.8 (237)a 37.8 (167)b 47.3 (26)b

1

Values expressed as Means±SE or percent (n)
P-values calculated using ANOVA or Chi-squared analysis.
3
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
4
MUAC at Delivery has sample size n = 1381, with IPTp 0,1,2,3,4 being n = 30, 262, 639, 397, and 53,
respectively.
5
Δ in Hemoglobin and Hemoglobin at 10 Weeks has sample size n = 1442, with IPTp 0, 1,2 ,3 ,4 being n =
36, 279, 659, 413, and 55, respectively.
2

There was no improvement observed in baseline data for MUAC at enrollment
(22.3 cm) and MUAC at delivery (22.2 cm) nor was there any statistical difference by
IPTp doses as shown in Table 3. Weight gain during treatment was higher among women
who received three or four IPTp doses and lowest in women receiving only one IPTp
dose (p-value < 0.0001) as. Shown in Table 3. Hemoglobin increased in all treatment
groups but was not different across IPTp doses. Malaria reported during treatment was
also not different across IPTp doses. Those receiving three or four IPTp doses during
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pregnancy had the highest proportion, 37.8 % and 47.3 % respectively, of women
achieving a MUAC ≥ 23 cm (p-value = 0.0020).
4.3 Adjusted Analysis of Maternal Health Outcomes by IPTp Dosing
Maternal health outcomes of weight gain during tx and achievement of MUAC ≥
23 cm were analyzed by IPTp doses after adjusting for maternal age, clinic region,
intervention, hemoglobin at enrollment (g/dL), education, weeks on treatment, and
seasonality. Models were fit with and without malaria during tx and malaria was not
found to statistically contribute to the model and therefore not included in models and
results reported below. As shown in Appendix B, univariate analysis of covariates and
IPTp dosing, there was a difference in proportion of women receiving IPTp doses based
on clinic region, education level, hemoglobin at enrollment, and weeks on treatment. The
highest proportion of women receiving IPTp doses occurred in Zomba (37.0 %) and
Chikhwawa (40.4 %) (p-value < 0.0001). Women with 4-6 and 7-8 years of education
had the highest proportion of women that received IPTp doses (37.2 %) and (26.1 %)
respectively (p-value = 0.0007). Also, women that received treatment the longest
received three or four IPTp doses throughout pregnancy (p-value < 0.0001).
4.3.1 Weight Gain During Treatment by Total IPTp Doses
The average weight gain during treatment for all women enrolled in the study was
2.69±2.6 kg with the highest weight gain during treatment seen with women in the RUSF
intervention group, 2.89±2.7 kg. After adjustment for age, clinic region, intervention,
hemoglobin at enrollment (g/dL), education, weeks on treatment, and seasonality,
differences in weight gain during tx across the IPTp doses was observed (p-value =
0.0017).
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Women receiving three total IPTp doses had statistically higher weight gains
during treatment than those receiving one IPTp dose: (Tukey HSD p-value = 0.0014).
The average weight gain was 3.08 [95% CI: 2.88, 3.55] kg for women receiving three
IPTp doses during treatment and 2.45 [95% CI: 2.24, 2.93] kg for those receiving one
IPTp dose.

Figure 7: Weight gain during treatment across total number of IPTp doses, doses during
the 2nd trimester, and doses during the 3rd trimester.
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4.3.2 Weight Gain During Treatment by IPTp Doses in the 2nd Trimester
Adjusted mean weight gain during treatment for zero, one, two, and three IPTp
doses given during the 2nd trimester was 2.50 kg [95% CI: 2.26, 3.00], 2.76 kg [95% CI:
2.59, 3.18], 2.95 kg [95% CI: 2.74, 3.42], and 2.27 kg [95% CI: 1.29, 3.43], respectively.
Statistically, there is no difference in weight gain during tx by any number of IPTp doses
received in the 2nd trimester (p-value = 0.0594). Although, the highest average weight
gain before adjustment, 3.14 kg, was observed from women receiving three IPTp doses
during the 2nd trimester, there is no statistical difference from those receiving any other
number of IPTp doses, and the least squares mean average was the lowest at 2.27 kg for
three IPTp doses, which may be attributed to having a low sample size of women
receiving three IPTp doses (n = 17). Four IPTp doses during the 2nd trimester has been
excluded from Figure 1 due to having n = 1.
4.3.3 Weight Gain During Treatment by IPTp Doses in the 3rd Trimester
IPTp doses given during the 3rd trimester, depicted in Figure 7, show a higher
weight gain during tx with increased IPTp doses (p-value = 0.0249) and women receiving
three IPTp doses had a statistically higher weight gain during tx than those receiving no
IPTp doses (Tukey HSD p-value = 0.0246). There was no difference in weight gain
during tx between women receiving zero, one, or two IPTp doses during the 3rd trimester
(p-value = 0.1605).
Adjusted mean weight gain by women receiving no IPTp doses was 2.62 kg [95% CI:
2.43, 3.06] while those receiving one, two, or three doses had greater weight gains of
2.78 kg [95% CI: 2.60, 3.21], 2.89 kg [95% CI: 2.68, 3.39], and 3.58 kg [95% CI: 3.01,
4.39], respectively (p-value = 0.0249).
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4.3.4 Weight Gain During Treatment and Covariates
There was a difference observed, univariately, for weight gain during tx for each
of the following covariates: seasonality, subject age, education, weeks on treatment, and
bed net use. Women gained 3.21 kg during tx, on average, during the dry season,
compared to 2.74 kg during the rainy season (p-value < 0.0001). Education, maternal age,
and weeks on treatment has a positive trendline with weight gain during tx. The older
maternal age, the higher weight gain during tx observed. More weeks on treatment,
intuitively, led to higher maternal weight gain during tx. Women that reported using a
bed net had average weight gain during tx of 3.07 kg compared to 2.65 kg for women that
reported not using a bed net (p-value = 0.0020).
4.3.5 Achievement of MUAC ≥ 23 cm by Total Number of IPTp Doses
The highest proportion of women achieving a MUAC ≥ 23 cm was 52.0 % seen in
women receiving four total IPTp doses (p-value = 0.0002). Women receiving three total
IPTp doses had a higher proportion achieve a MUAC ≥ 23 cm, 39.1 %, compared to
those receiving one IPTp doses, 26.8 % (Tukey HSD p-value 0.0020). There was no
statistical difference between those receiving three or four IPTp doses (Tukey HSD pvalue = 0.4321) and between three or two IPTp doses (Tukey HSD p-value = 0.0998);
however, those receiving four IPTp doses had a statistically higher proportion of women
achieve a MUAC ≥ 23 cm than those receiving two total IPTp doses (Tukey HSD p-value
= 0.0416). The data suggests that total IPTp doses are a strong predictor in women
achieving a MUAC ≥ 23 cm (p-value = 0.0002).
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Table 6: Achievement of MUAC ≥ 23 cm by IPTp Dosing
IPTp doses
Total Number IPTp
doses
IPTp doses 2nd
Trimester
IPTp doses 3rd
Trimester

Achievement of MUAC ≥ 23 cm
0
1
2
3
%
%
%
%
ab
26.5
26.8c
32.3bc 39.1ab
c

43
%

P-value

52.0a

0.0002

25.0a

34.1b

35.1b

28.3ab

-

0.0230

30.0

33.3

36.6

44.1

-

0.0808

1

The prevalence of achieving MUAC ≥ 23 cm across total number of IPTp doses after adjusting for age,
clinic region, intervention, hemoglobin at enrollment (g/dL), weeks on treatment, education, bed net use, and
seasonality.
2
Groups that do not share a common letter differ significantly (p-value < 0.05).
3
Missing data in column for four IPTp doses is because there are no women within the sample that received
four IPTp doses in the 3rd trimester and only one in the 2nd trimester, which was excluded.

4.3.6 Achievement of MUAC ≥ 23 cm by IPTp Doses in the 2nd Trimester
The number of IPTp doses during the 2nd trimester was associated with the
proportion of women achieving a MUAC ≥ 23 cm (p-value = 0.0230). Women receiving
one (Tukey HSD p-value = 0.0349) or two (Tukey HSD p-value = 0.0493) IPTp doses
during the 2nd trimester had a statistically higher proportion of women achieved a MUAC
≥ 23 cm than those receiving no IPTp doses during the 2nd trimester. There was no
difference observed for women receiving three IPTp doses during the 2nd trimester
compared to women receiving zero, one, or two IPTp doses (Tukey HSD p-value =
0.8350). A small sample size of 18 women received three IPTp doses during the 2nd
trimester led to a reduced power.
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Figure 8: The Prevalence of Achieving MUAC ³ 23 cm by Total Number of IPTp Doses

4.3.7 Achievement of MUAC ≥ 23 cm by IPTp Doses in the 3rd Trimester
Although there were no statistical differences, after adjustment, in proportions of
women achieving a MUAC ≥ 23 cm among women receiving IPTp doses during the 3rd
trimester (p-value = 0.0729), women receiving three IPTp doses during the 3rd trimester
had the highest proportion achieve a MUAC ≥ 23 cm with 45.8 %. As depicted in Figure
8, the data suggests that four IPTp doses received in the 3rd trimester, helped achieve a
37

MUAC ≥ 23 cm, but again, there is not statistically significant. The sample size for
women receiving 3 IPTp doses during the 3rd trimester was small with n = 47 leading to a
low power for comparisons with this group.
4.3.8 Achievement of MUAC ≥ 23 cm and Covariates
Seasonality, weeks on treatment, and bed net use all had statistical differences
observed when looking at unadjusted proportions of women achieving a MUAC ≥ 23 cm.
A higher proportion of women achieved a MUAC ≥ 23 cm during the dry season than the
rainy season (p-value < 0.0001). More women that reported using bed nets (38.47 %)
achieved a MUAC ≥ 23 cm than those that reported not using bed nets (32.20 %).
4.4 Maternal Hemoglobin and Anemia
Hemoglobin values at enrollment ranged between 7.0 g/dL and 15.5 g/dL with the
median at 10.1 g/dL. On average, improvements in hemoglobin values were observed
after receiving treatment for ten weeks. A similar pattern was seen in anemia status with
improvements between enrollment and after 10 weeks of treatment. At enrollment, 1280
(70.9 %) women were anemic and 603 (38.5 %) women were anemic at the second
measurement as shown in Table 7. The majority of anemic women at time of enrollment
were moderately anemic (Hemoglobin between 7.0 and 9.8 g/dL), while the majority of
anemic women at the second measurement 10 weeks later were mildly anemic
(hemoglobin between 9.9 and 11 g/dL). Hemoglobin values and anemia status at 10
weeks had a sample size of 1566 compared to 1805 at enrollment due to 239 women
delivering before they had been enrolled in the study for 10 weeks.
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Table 7: Baseline and Follow-up Maternal Hemoglobin and Anemia
N
Mean SD
Hemoglobin at Enroll (g/dL)

1805

10.1

1.5

Hemoglobin at 10 weeks (g/dL) 1566

11.3

1.7

Δ in Hemoglobin (g/dL)

1.2

1.8

1566

N
Anemia at Enroll (Hgb < 11 g/dL)

%

1280 70.9

Mild (Hgb 9.9 – 11 g/dL)

399 22.1

Moderate (Hgb 7.0 – 9.8 g/dL)

677 42.4

Anemia at 10 weeks (Hgb < 11 g/dL)

603 38.5

Mild (Hgb 9.9 – 11 g/dL)

305 51.1

Moderate (Hgb 7.0 – 9.8 g/dL)

295 18.8

1

Values expressed as Means and Standard Deviation (SD) or percent (n).

4.5 Unadjusted Maternal Health Outcomes by Hemoglobin and Anemia
To investigate whether hemoglobin or anemia had an impact on maternal weight
gain during treatment and recovery or achievement of MUAC ≥ 23 cm analysis was done
by adjusting for age, clinic region, intervention, education, weeks on treatment, total
number IPTp doses, bed net use, and seasonality. Model was fit with and without malaria
during tx and malaria was not found to statistically contribute to the model and therefore
not included in models. The effect of the changes in anemia status on weight gain and
MUAC were modeled by creating a new variable that tracked anemia status across both
observed times. The variable had four levels: no anemia, acquired anemia, recovered
anemia, and anemic at both measured times.
Women with one to three years of education or secondary and tertiary education
had higher hemoglobin values at enrollment than women of other education levels (pvalue = 0.0137). Women from the ANCs in Mulange and Zomba had higher hemoglobin
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at enrollment values (10.47 and 10.57 g/dL) than women attending ANCs in Chikhwawa
and Blantyre (9.80 and 9.84 g/dL) (p-value < 0.0001). When bed net use was reported,
hemoglobin at enrollment was higher, 10.17 g/dL, compared to no bed net use, 9.94 g/dL
(p-value = 0.0061).
Unadjusted hemoglobin at enrollment was not different across intervention groups
(p-value = 0.3108); however, hemoglobin after ten weeks and the change in hemoglobin
was different depending on the treatment group each woman was placed in. As shown in
Table 8 Hemoglobin after ten weeks was the highest in the CSB-UNIMMAP group (pvalue = 0.0214) and the biggest change in hemoglobin was observed in the CSB-IFA
group (p-value = 0.0166).
Table 8: Univariate Analysis of Hemoglobin by Intervention Group
Intervention
RUSF
CSBCSB-IFA
UNIMMAP
Hemoglobin at
enroll (g/dL)

10.17±0.1

10.21±0.1

Hemoglobin after
10 weeks (g/dL)

11.18±0.1

b

11.46±0.1

Δ Hgb (g/dL)

1.00±0.1

a

1.25±0.1

10.07±0.1

a

11.35±0.1

ab

1.28±0.1

P-Value
0.3108

ab

0.0214

b

0.0166

1

Values expressed as Means±Standard Error
Groups that do not share a common letter differ significantly (p-value < 0.05).

2

4.5.1 Adjusted Maternal Weight Gain During Treatment by Hemoglobin
After adjustment, hemoglobin at enrollment was a significant predictor of
maternal weight gain during treatment (p-value = 0.0111). Women entering the study
with hemoglobin values above the mean of 10.1 g/dL had a higher weight gain during
treatment than the average participant weight gain of 2.69±2.6 kg. A linear relationship
was observed; as hemoglobin increased, weight gain during tx increased.
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Figure 9: Hemoglobin at Enrollment as a Predictor of Maternal Weight Gain During Tx

After adjusting for covariates, the second hemoglobin measurement, taken after
10 weeks of treatment, was not a significant predictor of maternal weight gain during tx
(p-value = 0.7350). The change in hemoglobin however was a significant predictor of
weight gain during treatment (p-value = 0.0288). Change in hemoglobin was defined as
second measurement minus measurement at enrollment. Figure 10 shows that the greatest
weight gain during treatment occured when the hemoglobin at enrollment was lower than
hemoglobin at second measurement (negative Δ Hgb).

41

Figure 10: Change in Hemoglobin as a Predictor of Maternal Weight Gain During Tx
4.5.2 Adjusted Maternal Weight Gain During Treatment by Anemia
Anemia at enrollment, defined by hemoglobin < 11 g/dL, was not found to be a
predictor of maternal weight gain during tx. Both anemic and non-anemic women at
enrollment had average weight gains during treatment of 2.97 kg [anemic, 95% CI: 2.64,
3.30; non-anemic, 95% CI: 2.60, 3.33] (p-value = 0.9754). Anemia at the second
measurement was also not found to be a predictor of maternal weight gain during tx (pvalue = 0.0829) after adjusting for model covariates: age, clinic region, intervention,
education, weeks on treatment, total number IPTp doses, and seasonality.
Moderate anemia, defined as hemoglobin between 7.0 and less than 9.9 g/dL, at
enrollment was not a significant predictor of weight gain during treatment (p-value =
0.3484). Nor was mild anemia, defined as hemoglobin greater than or equal to 9.9, but
less than 11.0 g/dL, at enrollment (p-value = 0.4599). Neither mild nor moderate anemia
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at the second measure was found to be a predictor of weight gain during tx (p-value =
0.5010 and 0.2287, respectively).
4.5.3 Adjusted Achievement of MUAC ≥ 23 cm by Hemoglobin and Anemia
There was no difference in achievement of MUAC ≥ 23 cm observed when using
hemoglobin at enrollment, hemoglobin at the second measurement, or the change in
hemoglobin to predict the proportion of women that achieve a MUAC ≥ 23 cm (p-value =
0.1683, 0.7025, and 0.1808, respectively).
Similarly, to hemoglobin, anemia at enrollment, mild anemia at enrollment, and
moderate anemia at enrollment was not found to have a statistically significant
association with the proportion of women that achieve a MUAC ≤ 23 cm (p-values =
0.6445, 0.3165, and 0.9092, respectively). Anemia at 10 weeks, mild anemia at 10 weeks,
and moderate anemia at 10 weeks were also not found to predict achievement of MUAC
≤ 23 cm (p-values = 0.1896, 0.5569, and 0.2527, respectively).
4.6 Baseline: Infant Characteristics
Infant hemoglobin was measured at 3 months after birth and ranged between 2.5
g/dL and 15.5 g/dL and 76.59 % (n = 1099) were anemic at 3 months. Infant length at
birth ranged from 37.5 cm to 56 cm, at 6 weeks from 40.1 cm to 61.5 cm, and from 46.3
cm to 66 cm at 3 months. Infant weight at birth ranged from 0.6 kg to 4.72 kg, 6 weeks
from 1.55 kg to 6.76 kg, and from 2 kg to 8.09 kg at 3 months. Head circumference at
birth ranged from 27.9 cm to 39.5 cm, 6 weeks from 31.7 cm to 45.8 cm, and head
circumference from 34.1 cm to 49.4 cm at 3 months. Infant MUAC at birth ranged
between 6.2 cm and 13 cm, MUAC at 6 weeks ranged from 6.1 cm to 17.3 cm, and
MUAC at 3 months ranged from 7 cm to 18.5 cm
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Table 9: Baseline and Follow-up Infant Characteristics
Characteristic

N

Mean

SD

Hemoglobin at 3 months (g/dL)

1435

9.94

1.52

Anemia at 3 months

1435

10992

76.592

Birth

1431

47.1

2.21

6 weeks

1467

53.7

2.45

3 months

1449

58.2

2.53

Birth

1451

2.74

0.41

6 weeks

1467

4.37

0.64

3 months

1450

5.55

0.75

Birth

1395

34.2

1.49

6 weeks

1460

38

1.46

months

1445

40.3

1.52

Birth

1426

9.56

0.85

6 weeks

1467

11.8

1.08

1449

13.1

1.15

Length (cm)

Weight (kg)

Head Circumference (cm)

MUAC (cm)

3 months
1

SD represents standard deviation.
Anemia at 3 months represented as n and percent.

2
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Table 10: Baseline and Follow-up Infant Z-scores

LFA (Stunting)
Birth
6 weeks
3 months
WFA (Underweight)
Birth
6 weeks
3 months
WFL (Wasting)
Birth
6 weeks
months
HCFA (Small Head)
Birth
6 weeks
3 months
Stunted (LFA < -2)
Birth
6 Weeks
3 Months
Underweight (WFA < -2)
Birth
6 Weeks
3 Months
Wasting (WFL < -2)
Birth
6 Weeks
3 Months
Small Head (HCFA < -2)
Birth
6 Weeks
3 Months
1

N

Z-score

SD

1400
1267
1255

-1.29
-1.19
-1.19

1.19
1.17
1.15

1453
1267
1256

-1.28
-0.90
-0.87

0.98
1.06
1.06

1213
1258
1255

-0.48
0.29
0.19

1.03
1.03
1.08

1372
1262
1252

0.05
0.12
0.23

1.26
1.15
1.17

N

%

287
146
152

19.75
11.52
12.10

325
260
266

23.21
20.52
21.20

68
23
31

5.61
1.83
2.47

62
40
34

4.52
3.17
2.72

Values expressed as Means and Standard Deviation (SD) or percent (n).
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4.7 Unadjusted Infant Health Outcomes by IPTp

Characteristics
Hemoglobin at 3
Months (g/dL)
Anemia at 3 Months
Length (cm)
Birth

Table 11: Unadjusted Infant Health Outcomes Across Number of IPTp Doses Reported
Number of IPTp Doses Reported (n = 1347)
0
1
2
3
4
Overall
n = 32
n = 255
n = 621
n = 389
n = 50

P-value

10.05±0.3

9.87±0.1

9.89±0.1

10.09±0.1

10.07±0.2

9.96±0.1

0.2868

18 (56.3)

196 (79.4)

464 (76.3)

286 (74.5)

41 (80.4)

1099 (76.6)

0.8029

47.69±0.4ab

46.75±0.2b

47.12±0.1ab

47.30±0.1a

47.26±0.3ab

47.12±0.2

0.0198

6 Weeks

53.21±0.5ab

53.21±0.2b

53.84±0.1a

54.0±0.1a

54.20±0.3ab

53.78±0.2

0.0008

3 Months

58.39±0.4ab

57.86±0.2b

58.29±0.1ab

58.51±0.1a

58.57±0.3ab

58.29±0.2

0.0234

Birth

2.87±0.1a

2.66±0.03b

2.73±0.02ab

2.79±0.02a

2.81±0.05ab

2.74±0.02

0.0007

6 Weeks

4.42±0.1ab

4.24±0.04b

4.39±0.02a

4.46±0.03a

4.63±0.1a

4.39±0.1

<0.0001

3 Months

5.72±0.1ab

5.45±0.1b

5.56±0.03ab

5.65±0.04a

5.82±0.1a

5.58±0.1

0.0012

Birth

34.77±0.3a

33.95±0.1b

34.18±0.1ab

34.42±0.1a

34.43±0.2ab

34.24±0.1

0.0004

6 Weeks

37.85±0.3ab

37.81±0.1b

38.07±0.1ab

38.20±0.1a

38.61±0.2a

38.07±0.1

0.0010

3 Months

40.50±0.3ab

40.14±0.1b

40.30±0.1ab

40.55±0.1a

40.77±0.2a

40.37±0.1

0.0022

Weight (kg)

Head Circumference
(cm)

MUAC (cm)
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Birth

9.76±0.1ab

9.41±0.1b

9.54±0.03ab

9.66±0.04a

9.71±0.1ab

9.56±0.1

0.0026

6 Weeks

11.73±0.2ab

11.62±0.1b

11.89±0.04a

11.99±0.1a

12.26±0.1a

11.88±0.1

<0.0001

13.25±0.2

12.92±0.1

13.04±0.04

13.20±0.1

13.36±0.1

13.08±0.1

0.0068

3 Months
1

Values expressed as Means±SE
P-values calculated using ANOVA (continuous values).
3
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
2

Table 12: Unadjusted Infant Health Outcomes Compared Across Number of IPTp Doses Reported in Z-scores.
Number of IPTp Doses Reported
0

1

2

3

4

Overall

P-value

Birth

-1.07±0.2ab

-1.50±0.1b

-1.29±0.05ab

-1.17±0.1a

-1.18±0.2ab

-1.28±0.1

0.0157

6 Weeks

-1.28±0.2ab

-1.44±0.1b

-1.17±0.1a

-1.03±0.1a

-1.02±0.2ab

-1.18±0.1

0.0019

3 Months

-1.63±0.2ab

-1.40±0.1b

-1.19±0.05ab

1.00±0.1a

-0.92±0.2ab

-1.16±0.1

0.0002

Birth

-1.04±0.2ab

-1.47±0.1b

-1.28±0.04ab

-1.15±0.04a

-1.04±0.1ab

-1.27±0.01

0.0003

6 Weeks

-0.82±0.2ab

-1.17±0.1b

-0.88±0.04a

-0.74±0.1a

-0.48±0.2a

-0.88±0.1

< 0.0001

3 Months

-0.87±0.2ab

-1.08±0.1b

-0.87±0.04ab

-0.68±0.1a

-0.45±0.2a

-0.83±0.1

< 0.0001

Birth

-0.29±0.2

-0.46±0.1

-0.53±0.04

-0.44±0.1

-0.29±0.2

-0.48±0.2

0.3723

6 Weeks

0.52±0.2ab

0.20±0.1b

0.28±0.04ab

0.32±0.1ab

0.69±0.2a

0.30±0.1

0.0377

3 Months

0.69±0.2

0.14±0.1

0.19±0.05

0.22±0.1

0.45±0.2

0.21±0.1

0.0937

LFA

WFA

WFL
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HCFA
Birth

0.37±0.2ab

-0.19±0.1b

0.03±0.1ab

0.25±0.1a

0.24±0.2ab

0.07±0.1

0.0004

6 Weeks

-0.03±0.2ab

-0.04±0.1b

0.13±0.04ab

0.28±0.1a

0.52±0.2a

0.15±0.1

0.0027

3 Months

-0.003±0.2ab

0.05±0.1b

0.18±0.1b

0.49±0.1a

0.69±0.2a

0.27±0.1

< 0.0001

1

Values expressed as Means±SE
P-values calculated using ANOVA (continuous values).
3
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
2
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4.7.1 Infant Health Outcomes by Maternal IPTp Dosing During Pregnancy
The following sub-sections of this study examine the relationship between total
number of maternal IPTp doses received during pregnancy on infant outcomes:
hemoglobin at three months, anemia at three months, length, weight, head circumference,
and MUAC. The results in the below sections refer to adjusted mean values with
covariates being maternal MUAC at delivery, maternal malaria during treatment,
maternal age, clinic region, maternal weight gain during treatment, maternal hemoglobin
at enrollment, intervention, bed net use, and seasonality.
Unadjusted infant hemoglobin and anemia at three months was different when
comparing values by the following covariates: maternal hemoglobin at enrollment,
maternal weight gain during treatment, maternal age, clinic region, maternal MUAC at
delivery, and seasonality. Maternal hemoglobin at enrollment had a statistical effect on
infant length and weight, but not head circumference or MUAC. Infant length, weight,
head circumference, and MUAC were all statistically different by maternal weight gain
during treatment and MUAC at delivery. Unadjusted analysis of maternal age showed it
was a significant predictor of infant length, weight, and MUAC.
4.7.2 Adjusted Infant Hemoglobin and Anemia at 3 Months by IPTp
Total number of maternal IPTp doses during pregnancy had no statistically
significant effect on infant hemoglobin at 3 months (p-value = 0.7810). The average
hemoglobin at 3 months for zero, one, two, three, and four total number of IPTp doses
given to the mother during pregnancy are shown in Table 13. There was no statistical
difference observed in infant anemia at 3 months, defined by hemoglobin values below
11.0 g/dL, across total number of IPTp doses (p-value 0.8209).
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Table 13: Infant Hemoglobin and Anemia by Number of Total Number IPTp
Doses
Total Number of IPTp doses
0
1
2
3
4
Infant Characteristics
P-value
n = 32
n = 255
n = 621
n = 389
n = 50
Hemoglobin at 3 Months
10.00±0.2 10.00±0.1 9.92±0.1 10.05±0.1 9.90±0.2 0.7810
(g/dL)
Anemia at 3 Months
464
18 (56.3) 196 (79.4)
286 (74.5) 41 (80.4) 0.8209
(Hgb > 11 g/dL)
(76.3)
1

Values are adjusted means±SE or n (%)

4.7.3 Adjusted Infant Length by IPTp
After adjusting for maternal MUAC at delivery, malaria during treatment,
maternal age, clinic region, maternal weight gain during treatment, maternal hemoglobin
at enrollment, intervention, and seasonality, there was no statistically significant effect on
infant length at birth or 3 months by total number of maternal IPTp doses (p-value =
0.1752, 0.1498). There is some evidence that women receiving two or three IPTp doses
had infants with a statistically significant higher length at six weeks than those with
mothers receiving one IPTp doses (Tukey HSD p-value = 0.0247 and 0.0090,
respectively). The mean average infant length at six weeks for two IPTp is shown in
Table 14. No difference from total number of IPTp doses was observed with LFA (pvalue = 0.1040). As seen in Table 15, infants born to women that received three IPTp
doses during pregnancy had higher LFA z-scores at six weeks and three months than
infants born to women who received one IPTp dose (Tukey HSD p-value = 0.0056 and
0.0276, respectively).
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Table 14: Infant length by total number IPTp doses
Number of IPTp doses
0

1

2

3

4

Mean

Mean

Mean

Mean

Mean

47.68±0.4

46.80±0.2

47.09±0.1

47.17±0.2

47.11±0.3

P-value

Length (cm)
Birth
6 Weeks
3 Months

0.1752

53.78±0.5ab 53.23±0.2b 53.79±0.2a 53.90±0.2a 53.90±0.4ab 0.0163
58.72±0.5

58.00±0.2

58.37±0.2

58.48±0.2

58.44±0.4

0.1498

1

Values are adjusted means±SE.
2
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05)

Table 15: Infant LFA (Z-scores) by Total IPTp Doses
Number of IPTp doses
0
1
2
3
4
Mean
Mean
Mean
Mean
Mean
LFA (Z-score)
Birth
6 Weeks
3 Months

-1.22±0.3
-1.30±0.3ab
-1.43±0.3ab

-1.53±0.1
-1.51±0.1b
-1.40±0.1b

-1.31±0.1
-1.22±0.1a
-1.20±0.1ab

-1.24±0.1
-1.13±0.1a
-1.09±0.1a

-1.25±0.2ab
-1.09±0.2ab

1

Values are adjusted means±SE.
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).

2

4.7.4 Adjusted Infant Weight by IPTp
Total number of IPTp doses was a statistically significant predictor of infant
weight at birth, six weeks, and three months before and after adjustment. Infant weight at
birth was statistically higher in infants from women receiving three total IPTp doses than
one IPTp dose (Tukey HSD p-value = 0.0286).
Women receiving two, three, or four IPTp doses gave birth to infants with
statistically higher weights at six weeks than women receiving one IPTp dose (Tukey
HSD p-value = 0.0469, 0.0063, and 0.0271, respectively). Infants from women receiving
one IPTp dose during pregnancy had an average weight at six weeks of 4.26 [95% CI:
4.10, 4.32] kg compared to average weight at six weeks of 4.39 [95% CI: 4.26, 4.42] kg,
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P-value
0.0545
0.0147
0.0487

4.48 [95% CI: 4.29, 4.49] kg, and 4.61 [95% CI: 4.31, 4.69] kg for two, three, and four
IPTp doses, respectively. Women receiving no IPTp doses during pregnancy gave birth to
infants with statistically higher weight at 3 months than infants from women receiving
one IPTp dose (Tukey HSD p-value = 0.0471).
IPTp dosing was a significant predictor of infant WFA (p-value = 0.0024). Infants
from mothers that received two or three IPTp doses had statistically higher WFA zscores, -1.32±0.1 and -1.22±0.1, than infants whose mothers received one IPTp dose, 1.50±0.1 (Tukey HSD p-value = 0.0343 and 0.0016, respectively). Seen in Table 17,
infant WFA at six weeks was significantly improved in infants whose mother’s received
two, three, or four IPTp doses during pregnancy than infants whose mother’s received
one IPTp dose (Tukey HSD P-values = 0.0049, 0.0005, and 0.0110, respectively). At
three months, three IPTp doses had a significantly improved z-score than one IPT dose
(Tukey HSD p-value = 0.0083). Although not statistically significant, a positive trendline
is observed from one IPTp dose to four IPTp doses, values improving with each
additional dose.
Proportionately, WFA z-scores at birth below two standard deviations of the mean
(> -2) were statistically different by IPTp dosing when considering the overall p-value of
0.0458; however, Tukey HSD was unable to identify any difference between individual
groups. 11.1 % of infants from women receiving no IPTp doses during pregnancy had
WFA z-scores below -2 compared to 26.4 %, 22.3 %, and 18.0 % of infants whose
mothers received one, two, or three IPTp doses. While no individual pairing is
statistically significant, there is almost 8 % fewer infants stunting from women receiving
three IPTp doses compared to one IPTp dose.
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Table 16: Infant Weight by Total Number IPTp Doses
Number of IPTp doses
0

1

2

3

4

P-value

n=
Weight (kg)
Birth
6 Weeks
3 Months

2.84±0.1ab 2.64±0.03b 2.70±0.03ab 2.74±0.03a 2.75±0.1ab
4.48±0.1ab 4.26±0.1b 4.39±0.04a 4.48±0.05a 4.61±0.1a
5.84±0.2a 5.43±0.1b 5.50±0.1ab 5.56±0.1ab 5.67±0.1ab

0.0117
0.0041
0.0133

1

Values are adjusted means±SE.
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).

2

Table 17: Infant WFA (Z-scores) by Total IPTp Doses
Number of IPTp doses
0
1
2
3
4
WFA (Z-score)
Birth
6 Weeks
3 Months

-1.13±0.2ab
-0.83±0.3ab
-0.58±0.3ab

-1.52±0.1b
-1.25±0.1b
-1.08±0.1b

-1.32±0.1a
-0.93±0.1a
-0.90±0.1ab

-1.22±0.1a
-0.85±0.1a
-0.76±0.1a

-0.68±0.2a
-0.63±0.2ab

1

Values are adjusted means±SE.
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
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4.7.5 Adjusted Infant Head Circumference by IPTp
Total number of maternal IPTp doses during pregnancy was not found to be a
statistically significant predictor of infant head circumference at birth (p-value = 0.8661).
Three total maternal IPTp doses during pregnancy had a statistically higher head
circumference at birth than one IPTp dose (Tukey HSD p-value = 0.0227). Although the
effect of total number of IPTp doses on head circumference at six weeks was found to
have a statistical p-value below 0.05 (p-value = 0.0402); there was no difference between
any observations for head circumference at six weeks as shown in Table 18. There was a
difference observed for total number of IPTp doses and head circumference measured at
three months (p-value 0.0205). Women receiving three doses of IPTp gave birth to
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P-value

0.0024
0.0004
0.0050

infants with statistically higher head circumference values at three months than infants
from mothers who were administered one total IPTp dose during pregnancy (Tukey HSD
p-value = 0.0353). There was no observable statistical difference between infant head
circumference at three months between zero, two, or four IPTp doses.
Infant HCFA z-scores at birth were different by IPTp dosing after adjustment for
covariates (p-value = 0.0064) as shown in Table 19. Infants whose mothers received three
IPTp doses during pregnancy had improved z-scores compared to infants whose mothers
received one IPTp dose during pregnancy (Tukey HSD p-value = 0.0035). At six weeks,
no statistical difference was observed for HCFA z-scored by IPTp doses; however, a
positive trend was observed, or an improved z-score with each additional IPTp dose was
seen. At three months, a similar pattern was observed for HCFA z-scores as at birth; three
IPTp doses had improved z-scores than one IPTp dose.
Table 18: Infant Head Circumference by Total Number of IPTp Doses
Number of IPTp doses
Infant
P0
1
2
3
4
Characteristics
value
%
%
%
%
%
Head Circumference
Birth
34.73±0.3ab 33.94±0.1b 34.13±0.1ab 34.32±0.1a 34.26±0.2ab 0.0086
6 Weeks
37.73±0.3 37.70±0.1 37.97±0.1 38.00±0.1 38.27±0.2 0.0402
3 Months
40.66±0.3ab 40.07±0.1b 40.27±0.1ab 40.43±0.1a 40.57±0.2ab 0.0205
1

Values are adjusted means±SE
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
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Table 19: Infant HCFA (Z-scores) by Total IPTp Doses
Number of IPTp doses
0
1
2
3
4
HCFA (Z-score)
Birth
6 Weeks
3 Months

0.19±0.3ab
-0.10±0.3ab
0.02±0.3ab

-0.20±0.1b
-0.13±0.1b
-0.01±0.1b

0.01±0.1ab
0.09±0.1a
0.20±0.1ab

0.18±0.1a
0.14±0.1a
0.41±0.1a

0.29±0.2a
0.50±0.2ab

1

Values are adjusted means±SE.
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
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4.7.6 Adjusted Infant MUAC by IPTp
Significant differences in infant MUAC by total number of maternal IPTp doses
during pregnancy were seen at birth and six weeks, but not three months. At birth, infants
from mothers who received three total IPTp doses had a statistically higher MUAC at
birth of 9.55 [95% CI: 9.43, 9.68] cm compared to those from women receiving one total
IPTp dose, 9.33 [95% CI: 9.18, 9.47] cm (Tukey HSD p-value = 0.0096). Infant MUAC
at six weeks was statistically higher in infants with mothers that received two, three, or
four total IPTp does compared to women that received one total IPTp dose during
pregnancy (Tukey HSD p-value = 0.0343, 0.0073, and 0.0259, respectively). Infants from
women receiving one IPTp dose during pregnancy had average MUAC values at six
weeks of 11.47 [95% CI: 11.29, 11.65] cm. Although total number of IPTp doses found
to be a statistically significant predictor of infant MUAC at 3 months (p-value = 0.0327),
there was no evidence of a difference in predicting infant MUAC at 3 months whether the
mother had between zero and four IPTp doses.
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P-value

0.0064
0.0586
0.0014

Table 20: Infant MUAC by Total Number of IPTp Doses
Number of IPTp doses
Infant Characteristics

Pvalue

0

1

2

3

4

%

%

%

%

%

9.58±0.2ab

9.33±0.1b

9.47±0.1ab

9.55±0.1a

9.58±0.1ab

0.0289

MUAC
Birth
6 Weeks
3 Months

11.53±0.2

ab

13.32±0.2

b

11.71±0.1

a

11.77±0.1

a

11.97±0.2

a

0.0037

12.77±0.1

12.82±0.1

12.96±0.1

13.07±0.2

0.0327

11.47±0.1

1

Values are adjusted means±SE
Groups that do not share a common letter differ significantly (Tukey’s HSD p-value < 0.05).
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4.7.7 Summary of Infant Outcomes by IPTp
Total number of IPTp doses received during pregnancy did not have a statistical
effect on infant hemoglobin or anemia at three months. Infant length at six weeks was
higher in infants from mothers that received two or three IPTp doses compared to
mothers that received one IPTp dose (p-value = 0.0218). A p-value below 0.05 by total
number of IPTp doses was observed for infant weight, head circumference, and MUAC
at birth, six weeks, and three months. With a few exceptions described in the sections
above, the general trend observed was women receiving three IPTp doses gave birth to
infants with higher weight, head circumference, and MUAC values than infants from
mothers that received one IPTp dose during pregnancy.
4.8 Adjusted Infant Health Outcomes by Hemoglobin/Anemia
Only infant characteristics at three months were considered when looking at the
effect of infant hemoglobin and anemia at three months. Observable differences were
seen in infant length at three months by infant hemoglobin at three months (p-value =
0.0266). A positive trendline was observed, the higher infant hemoglobin values at three
months, the longer infant lengths at three months were on average. No differences were
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observed with infant weight, head circumference, or MUAC at three months (p-value =
0.0797, 0.8034, and 0.1659, respectively). In terms of infant anemia, defined by
hemoglobin below 11.0 g/dL, there was no effect of infant anemia observed for infant
length, weight, head circumference, or MUAC at three months.
4.9 Adjusted Infant Health Outcomes by Maternal Hemoglobin and Anemia
Maternal hemoglobin at study enrollment were found to have a statistically
significant effect on infant hemoglobin at three months (p-value = 0.0071). A positive
trendline was observed, meaning that higher maternal hemoglobin values at enrollment
yielded higher infant hemoglobin values, on average, at three months. Maternal
hemoglobin measured at 10 weeks after enrollment was not found to be a predictor of
infant hemoglobin at three months (p-value = 0.3501); therefore, maternal hemoglobin at
enrollment was a stronger predictor of infant hemoglobin at three months. No observable
differences were seen with change in maternal hemoglobin (second measurement minus
first measurement) on infant hemoglobin at three months.
Maternal hemoglobin at enrollment had no statistical effect on any infant
outcomes analyzed, see Table 21. Significant differences were observed in length (cm) at
birth, six weeks, and three months, as well as head circumference (cm) at birth and six
weeks, when using the second maternal hemoglobin measurement, taken 10 weeks after
enrollment. A positive trendline was observed; a higher maternal hemoglobin at the
second measurement yielded, on average, higher infant length at birth, six weeks, and
three months. Similarly, a higher maternal hemoglobin at the second measurement,
yielded, on average, higher infant head circumference at birth and six weeks. Although
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length was statistically impacted by the second maternal hemoglobin measurement, there
was no difference observed in LFA (p-value = 0.1066)

Table 21: Infant Outcomes by Maternal Hemoglobin at Enrollment and at 10
Weeks After Enrollment
Maternal Hgb at Enroll (n
= 1225)
P-value
Length (cm)
Birth
6 Weeks
3 Months
Weight (kg)
Birth
6 Weeks
3 Months
Head Circumference (cm)
Birth
6 Weeks
3 Months
MUAC (cm)
Birth
6 Weeks
3 Months

Maternal Hgb at 10
weeks (n = 1158)
P-value

0.1118
0.9524
0.9277

0.0294
0.0452
0.0139

0.7345
0.428
0.5073

0.431
0.108
0.4502

0.5378
0.7756
0.9649

0.0306
0.0349
0.0633

0.7534
0.4449
0.6422

0.4781
0.3358
0.6241

1

Hgb represents hemoglobin (g/dL).
P-values < 0.05 represent a statistical difference observed based on student’s t-test.
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4.10 Adjusted Infant Health Outcomes by Maternal Anemia
No statistical differences were observed for infant hemoglobin at three months by
maternal anemia, regardless of anemia at enrollment or anemia at second measurement
during treatment (p-value = 0.0995 and 0.6767, respectively). Similarly, there is no
evidence that either maternal anemia at enrollment or at 10 weeks were statistically
significant predictors of any infant outcomes measured. See Table 12 below for more
details. When considering severity of anemia, shown in Table 23, infants whose mothers

58

had moderate anemia at enrollment had statistically lower length at six weeks and three
months as well as lower weight and head circumference at six weeks than their respective
counterparts. As far as severity of anemia after ten weeks of study participation, only
infant MUAC at three months was statistically different, lower in this case, in infants
whose mothers were moderately anemic after ten weeks (p-value = 0.0220).
Table 22: Adjusted Infant Health Outcomes by Maternal Anemia at Enrollment
and at 10 Weeks After Enrollment
Maternal Anemia at Enroll
Maternal Anemia at 10 weeks
P-value
P-value
Length (cm)
Birth
0.8841
0.0816
6 Weeks
0.4411
0.2658
3 Months
0.9179
0.2183
Weight (kg)
Birth
0.3486
0.7269
6 Weeks
0.4585
0.8778
3 Months
0.9115
0.3489
Head Circumference (cm)
Birth
0.981
0.2294
6 Weeks
0.4668
0.3595
3 Months
0.9027
0.6137
MUAC (cm)
Birth
0.5723
0.1987
6 Weeks
0.4297
0.7939
3 Months
0.9502
0.0641
1

Anemia is defined as hemoglobin values below 11.0 g/dL.
P-values < 0.05 represent a statistical difference observed based on student’s t-tes
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Table 23: Adjusted Infant Health Outcomes by Severity of Maternal Anemia at
Enrollment and at 10 Weeks After Enrollment
Maternal Anemia at Enroll
Maternal Anemia at 10 weeks
Mild
Moderate
Mild
Moderate
P-value
P-value
P-value
P-value
Length (cm)
Birth
6 Weeks
3 Months
Weight (kg)
Birth
6 Weeks
3 Months

0.1172
0.0509
0.3123

0.1491
0.0062
0.0241

0.2275
0.9120
0.2851

0.5124
0.6363
0.1351

0.0651
0.3448
0.4016

0.3219
0.0385
0.2635

0.3732
0.2284
0.3218

0.6939
0.2670
0.0664
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Head
Circumference
(cm)
Birth
6 Weeks
3 Months
MUAC (cm)
Birth
6 Weeks
3 Months

0.0540
0.2384
0.5680

0.1143
0.0415
0.3236

0.2594
0.2212
0.2748

0.4176
0.2481
0.0849

0.4001
0.8027
0.2123

0.8292
0.7071
0.9332

0.9830
0.1651
0.1788

0.6026
0.1125
0.0220

1

Anemia is defined as hemoglobin values below 11.0 g/dL.
P-values < 0.05 represent a statistical difference observed based on student’s t-test.
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CHAPTER 5:
DISCUSSION
In the current secondary analysis of data from a randomized controlled clinical
trial, we found that intermittent preventative treatment in pregnancy (IPTp) with
sulfadoxine-pyrimethamine (SP) was a significant predictor of maternal weight gain
during treatment and achievement of MUAC ≥ 23 cm, as well as several infant health
outcomes. We also found that hemoglobin, at enrollment and measured after 10 weeks of
enrollment, was a significant predictor of maternal and infant outcomes observed in the
study. There was no evidence that IPTp usage reduced the prevalence of malaria during
treatment as shown in Table 5.
5.1 IPTp
Four total number of IPTp doses had the highest overall maternal weight gain
during treatment, followed by two and three total IPTp doses. Women receiving one IPTp
dose during pregnancy had the lowest weight gains. As far as dose timing, it was more
important to consider total number of IPTp doses during pregnancy rather than the timing
of the doses. Both in the 2nd and 3rd trimester, the data would suggest that the more doses
received during either trimester had a positive effect on weight gain during treatment, but
there was no statistical data in 2nd trimester when distinguishing between the effect of
women receiving one, two, or three IPTp doses, and there were only statistically
significant differences observed between three IPTp and one IPTp dose during the 3rd
trimester.
A statistical difference was observed in the proportion of women achieving a
MUAC ≥ 23 cm by total number of IPTp doses. The greatest proportion of women, after
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adjustment, that achieved a MUAC ≥ 23 cm was seen in women receiving four (47.3 %)
and three (37.8 %) total IPTp doses during pregnancy. Women receiving only one IPTp
dose during pregnancy had the lowest proportion of women that achieved a MUAC ≥ 23
cm. Results would suggest that total number of IPTp doses correlates closely with
achieving a MUAC ≥ 23 cm during pregnancy with recommendations being three or four
total IPTp doses during pregnancy and one or two doses being received during the second
trimester. IPTp doses received during the third trimester had a positive trendline
correlating higher proportions of women that achieved a MUAC ≥ 23 cm with more IPTp
doses received; however, there was no statistically significant evidence that there was any
difference observed.
We also observed improvements in infant length, weight, head circumference, and
MUAC at multiple time points by IPTp dosing. Most notably, the greatest improvements
were seen in infant weight at birth, six weeks, and three months. The general trend
observed was that women receiving three IPTp doses during pregnancy gave birth to
infants with improved anthropometrics compared to infants born from women receiving
one IPTp dose during pregnancy. A study done by Cates et al. showed similar results
with women receiving three or more IPTp doses having a significantly reduced risk for
LBW from 9.9 % to 6.9 % or roughly a 30 % decrease in incidence (Cates, 2018).
Another study conducted in Malawi also showed that two or more IPTp doses reduced
the incidence of LBW (Gutman, 2013).
Although the primary purpose behind IPTp dosing is to decrease the prevalence of
malaria; it was not actually significantly different by IPTp dosing in the study, and we
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observed improvements in maternal weight gain and achievement of MUAC ≥ 23 cm as
well as infant outcomes, primarily birth weight.
Several studies have investigated the metabolic pathways for IPTp-SP dosing and
its effect on outcomes unrelated to malaria, but the pathways remain largely undefined
outside of the concept of the role of SP in inhibition of folate metabolism. A study done
by Gutman et al. presumed that IPTp-SP improved LBW due to its antibacterial or antiinflammatory properties (Gutman, 2017). Another possible mechanism involves SP
causing alterations in the bacterial flora of the gut or reductions in the genitourinary tract
organisms associated with adverse pregnancy outcomes, leading to effects on both
maternal and infant weight gain (Dingens, 2016). A study done by Chico et al. showed
SP to be an antibiotic that likely exerts an inhibitory effect against nonmalarial causes of
LBW and pre-term delivery (Chico, 2015). There is significant research linking SP to
reductions in many bacteria related to urinary tract infections, such as P. jiroveci
pneumonia and Toxoplasma gondii (Chico, 2017), as well as SP was commonly used to
treat N. gonorrhoeae before penicillin was developed (Schurmann, 2002). The theory
behind the effectiveness of SP in reducing common bacteria associated with adverse
pregnancy outcomes is women receiving a dose at each ANC decreases the overall
bacteria load, reducing the incidence of adverse birth outcomes (Chico, 2017). There is
also some evidence that SP exposure inhibits maternal inflammatory responses to
infections that are known to trigger preterm delivery (von Linsingen, 2016).
Research is mixed of the effect of IPTp on anemia. In our sub-study there was no
statistical difference observed in proportion of anemic women by IPTp dosing after
adjusting for covariates. A study done by Kayentao et al. showed that IPTp dosing
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decreased the prevalence of several maternal anemia (Kayentao, 2013), while another
study showed that women receiving IPTp doses are 80 % less likely to be anemic
(Wilson, 2011). Other studies correlated with our results showing no difference in the
prevalence of anemia across IPTp doses (Harrington, 2011, and Mosha, 2014). No studies
were found that showed IPTp dosing had a significant effect on hemoglobin values;
however, a study done by Orish et al. showed an increase in hemoglobin values with
women receiving three IPTp doses, but the values were not statistically significant (Orish,
2015).
5.2 Hemoglobin and Anemia
Maternal weight gain correlated closely with hemoglobin at enrollment (p-value =
0.0111). The range for hemoglobin at enrollment was between 7.0 and 15.5 g/dL and the
higher hemoglobin values were found to correlate to higher weight gains during
treatment. Hemoglobin after ten weeks of study participation did not have a statistical
effect on weight gain during treatment, but the difference between first and second
hemoglobin measurements did. We observed that women with a lower difference
between first and second hemoglobin measurement (greater negative Δ Hgb value) had
the highest weight gains.
Anemia status, defined by hemoglobin less than 11.0 g/dL, was not found to
predict maternal weight gain. Women, both anemic and non-anemic at enrollment had a
2.97 kg, on average, weight gain during treatment (p-value= 0.9754). Similarly, anemia
status at the second measurement did not predict maternal weight gain. We examined the
relationship between the severity of anemia, defining mild (Hgb between 7 and 9.9 g/dL)
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and moderate anemia (greater than or equal to 9.9 g/dL, but less than 11.0 g/dL, and did
not observe any statistically significant results.
The change in hemoglobin was a significant predictor of achievement of MUAC
≥ 23 cm. Women with a higher change in hemoglobin were 1.08 times more likely to
achieve a MUAC ≥ 23 cm (p-value = 0.0271). This is consistent with previous studies,
which showed increased hemoglobin values led to increased MUAC (Laghari, 2017).
Other studies confirm our findings, showing anemia to be associated with low MUAC
(Ghosh, 2019), and a study done in Ethiopia showed that a MUAC > 23 cm reduced the
odds of anemia during pregnancy by 41 %. While we were unable to find a direct
association between anemia status and achievement of MUAC ≥ 23 cm, we did observe a
relationship between anemia after ten weeks and MUAC at delivery. Women that were
anemic after ten weeks had a lower MUAC at delivery (p-value = 0.0024).
Low pre-pregnancy BMI or fast gestational weight gain (GWG) was been
correlated to higher risk of iron deficiency anemia (Tan, 2018). In our study, we found
lower hemoglobin to be correlated with lower weight gain, which is opposite of findings
by Campos et al. showing low hemoglobin and high prevalence of anemia to be
associated with excessive weekly weight gain (Campos, 2019). In their study, the
reasoning was attributed to hemodilution, leading to an increased ratio of plasma volume
to erythrocytes, or a physiological anemia. Lao et al. had results similar to ours, showing
that iron deficiency anemia is associated with a decreased weight gain during pregnancy
(Lao, 2004).
There was no observed effect of maternal anemia status at either time point on
any infant outcomes monitored. Our research does not include women that were
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classified as having severe anemia, hemoglobin less than 7.0 g/dL, therefore, we only
examined the relationship between mild and moderate maternal anemia and infant
outcomes. We found that moderate maternal anemia was a predictor of infant length,
weight, and head circumference at six weeks and three months, but mild maternal anemia
at enrollment was not a significant predictor. The association between maternal anemia
and LBW is largely controversial. Some previous research has shown no association
among maternal anemia and infant anemia (Shao, 2012, and Solange, 2015). Maternal
anemia has been linked to increased morbidity and risk of fetal demise (Abu-Ouf, 2015)
and a study in Beninese showed severe anemia to increase the risk of LBW (BodeauLivinec, 2011).
A study done in Pakistan and India showed that only severe anemia was able to
statistically predict differences in infant outcomes (Parks, 2019). Another piece of
research suggests that anemia, regardless of severity, is an important predictor of infant
outcomes (Tunkyi, 2018). A study conducted by Menon et. al in India showed that it was
important to consider the trimester the mother was anemic and found that anemia in the
second trimester had the greatest statistical predicting power for infant outcomes (Menon,
2016). A study in Benin, West Africa, strongly linked the prevalence of malaria in
pregnant women to reduced infant hemoglobin through the first year of life
(Accrombessi, 2015). Another study done in Malawi showed that use of iron
supplementation as well as antimalarial procedures during pregnancy improved infant
hemoglobin. (Le Chessie, 2002).
5.3 Strengths and Limitations
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This study had a few major strengths, which include the method of data analysis,
through its randomization. The study included a large sample number and comprehensive
data collection for several different variable of interest, which helped rule out any
confounding variables that may be at play.
When trying to observe the effects of no IPTp or four IPTp doses, our study
lacked power due to a low sample size. While we found significant improvements for
both maternal and infant health outcomes when three IPTp doses were given during
pregnancy, we were unable to have the consistent ability to see any effect four IPTp
doses had; similarly, no IPTp doses had several observed outcomes that were unable to
be fully interpreted.
The average weeks spent enrolled in the study was around nine weeks, which
explains why the second hemoglobin sample size was smaller than hemoglobin at
enrollment. The average gestational age at enrollment of women in the study was twentyfour weeks; however, fundal height was used to determine gestational age, which women
often delivered with fundal heights well below 40 cm. Well-nourished and severely
malnourished women were excluded from the study, which limited the scope of inference
for our results. It would have been beneficial to observe health outcomes of severely
malnourished women as previous research has indicated benefits of IPTp dosing in
severely malnourished populations. Human error, misreporting, and lack of adherence
also serve as limitations to this study.
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CHAPTER 6:
CONCLUSION
All the data analyzed showed that women receiving three or four IPTp doses had
statistically improved maternal and infant outcomes or at least a positive trend towards
improved outcomes if not statistically significant. Maternal hemoglobin was also found to
be a statistically significant predictor of maternal and some infant outcomes.
We hypothesized women receiving less than three total IPTp doses during
pregnancy or having low hemoglobin would have lower weight gain during treatment as
well as a lower proportion of women that achieve a MUAC ≥ 23 cm. We found that
women receiving three of four IPTp doses had the biggest improvements in weight gain
and achievement of MUAC ≥ 23 cm. When considering the timing of IPTp doses, three
IPTp doses had improvements in maternal weight gain during treatment over one IPTp
dose during the third trimester. Women receiving any number of IPTp doses during the
second trimester had a higher proportion of women achieve a MUAC ≥ 23 cm. We found
that hemoglobin was directly proportional, with a positive trendline, to weight gain
during treatment. This is the first research, to our knowledge, that examined the
predictability of maternal weight gain during treatment and achievement of MUAC ≥ 23
cm by IPTp dosing or maternal hemoglobin.
Another key analysis we performed examined if maternal hemoglobin or number
of IPTp doses had any predicting power for infant outcomes at birth, six weeks, and three
months. The relationship between maternal hemoglobin or IPTp dosing had been studied
extensively in the past and our findings are consistent with previous research.
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IPTp dosing and maternal hemoglobin is important to consider when predicting
both maternal and infant outcomes. These results indicate that further research is needed.
IPTp dosing is closely related to illness or malaria and while receiving IPTp limits
malaria in a population, illness should be considered when predicting maternal and infant
outcomes. It would also be important to consider previous history of illness as we found
many outcomes were statistically significantly affect by hemoglobin at enrollment, or a
piece of the woman’s baseline health entering the study. Further research should also be
done to address whether there are improved outcomes with women receiving four IPTp
doses compared to three IPTp doses.
Implications of this research are consistent with previous research in that IPTp-SP
doesn’t just improve maternal and infant health outcomes by reducing the prevalence of
malaria as we did not observe a difference in prevalence of malaria by IPTp-SP dosing.
Our results are consistent with guidelines issued by the WHO that women should
receiving at least three doses of IPTp during pregnancy, beginning early in the second
trimester. Research should be done in the future to assess if there are biological adaptions
over time that interfere with undernourished populations’ ability to become replete or if
global criteria apply to undernourished populations in Sub-Saharan Africa.
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APPENDIX:
Appendix Table A: Nutrient Composition and Comparison by Treatment
CSB+UNIMMAP1
CSB-IFA2
Amount (%RDA) Amount (%RDA)

Nutrient

RUSF
Amount (%RDA)

Energy (kcal)
Protein (g)

920
36

893
33

893
33

α-linolenic acid (g)

2.26 (161)

0

0

Linoleic acid (g)

13.96 (107)

0

0

Vitamin A (µg)

2628 (341)

3210 (417)

2410 (312)

Vitamin B1
(Thiamin; mg)

3.2 (228)

1.7 (121.5)

0.3 (20)

Vitamin B2
(Riboflavin; mg)
Niacin (B3; mg)

3.8 (270)

4.7 (355)

3.29 (235)

35 (194)

36.8 (204)

18.8 (104)

Vitamin B6 (mg)

4.0 (210)

5.9 (198)

4.0 (210)

Vitamin B12 (µg)

5.5 (262)

7.3 (253)

4.7 (181)

Folic acid (µg)

574 (143)

659 (165)

659 (163)

Vitamin C (mg)

170 (200)

281 (331)

211 (249)

Vitamin D (µg)

30 (200)

20.9 (206)

25.4 (169)

Vitamin E (mg)

39.2 (261)

29.5 (197)

19.5 (130)

Vitamin K (µg)

192 (213)

70.5 (78)

70.5 (78)

Iodine (µg)

300 (136.4)

244 (170)

94 (43)

Copper (µg)
Iron (mg)

2400 (240)
45 (170)

2000 (200)
45.3 (180.7)

0
79.2 (292)

Zinc (mg)

24.6 (223)

26.8 (243)

11.8 (107)

Magnesium (mg)

327 (93)

0

0

Calcium (mg)

1830 (183)

851 (85)

851 (85)

Selenium (µg)

123 (205)

65 (108)

0

1

Estimates a daily portion of 235 g CSB+ per day plus UNIMMAP supplement
2
Estimates a daily portion of 235 g CSB per day plus iron (60 mg) and folic acid (400 µg)
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Appendix Table B: Univariate Analysis of IPTp Doses and Categorical Covariates.

Characteristics
Intervention
RUSF
CSB-IFA
CSB-UNIMMAP
Seasonality
Rainy
Dry
Clinic Region
Blantyre
Chikhwawa
Mulange
Zomba
Education
None
1-3 years
4-6 years
7-8 years
Secondary
Tertiary
1

0
n (%)

Total Number of IPTp Doses (n = 1648)
1
2
3
n (%)
n (%)
n (%)

4
n (%)

Overall n
(%)

P-value
0.0461

19 (1.2)
15 (0.9)
9 (0.6)

117 (7.1)
126 (7.7)
120 (7.3)

246 (14.9)
230 (14.0)
269 (16.3)

152 (9.2)
169 (10.3)
121 (7.3)

19 (1.2)
16 (1.0)
20 (1.2)

553 (33.6)
550 (33.4)
545 (33.1)
0.3524

13 (0.8)
30 (1.8)

130 (7.9)
233 (14.1)

240 (14.6)
505 (30.6)

130 (7.9)
312 (18.9)

15 (0.9)
40 (2.4)

528 (32.0)
1120 (68.0)
< 0.0001

8 (0.5)
27 (1.6)
3 (0.2)
5 (0.3)

62 (3.8)
173 (10.5)
17 (1.0)
111 (6.7)

118 (7.2)
305 (18.5)
54 (3.3)
268 (16.3)

90 (5.5)
147 (8.9)
9 (0.6)
196 (11.9)

11 (0.7)
13 (0.8)
1 (0.1)
30 (1.8)

289 (17.5)
665 (40.4)
84 (5.1)
610 (37.0)
0.0007

5 (0.3)
10 (0.6)
17 (1.0)
7 (0.4)
4 (0.2)
0 (0)

54 (3.3)
66 (4.0)
129 (7.8)
75 (4.6)
37 (2.3)
2 (0.1)

79 (4.8)
104 (6.3)
271 (16.5)
198 (12.0)
88 (5.3)
4 (0.2)

P-values calculated using Chi-squared analysis.
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28 (1.7)
54 (3.3)
174 (10.6)
126 (7.7)
57 (3.5)
3 (0.2)

1 (0.1)
4 (0.2)
21 (1.3)
24 (1.5)
5 (0.3)
0 (0)

167 (10.1)
238 (14.5)
612 (37.2)
430 (26.1)
191 (11.6)
9 (0.6)

Appendix Table C: Univariate Analysis of IPTp Doses and Continuous Covariates
Total Number of IPTp Doses (n = 1648)
0

1

2

3

4

n = 43

n = 363

n = 745

n = 442

n = 55

10.22±0.07a

10.20±0.2ab

10.47±0.3a

12.2±0.8a

Hemoglobin at
enrollment
(g/dL)

10.03±0.3ab

Weeks on
Treatment

7.80±0.8bc

9.89±0.08

10.24±0.05

b

a

7.48±0.3c

8.92±0.2b

88

Overall
10.15±0.0
5
9.1±0.1

P-value

0.0044
<0.000
1

